BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333:328-335. [PMID: 15961063 DOI: 10.1016/j.bbrc.2005.05.132] [Cited by in Crossref: 586] [Cited by in F6Publishing: 523] [Article Influence: 34.5] [Reference Citation Analysis]
Number Citing Articles
1 Ran S, Volk L, Hall K, Flister MJ. Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology 2010;17:229-51. [PMID: 20036110 DOI: 10.1016/j.pathophys.2009.11.003] [Cited by in Crossref: 146] [Cited by in F6Publishing: 146] [Article Influence: 11.2] [Reference Citation Analysis]
2 Uy AL, Simper NB, Champeaux AL, Perkins RM. Progressive bevacizumab-associated renal thrombotic microangiopathy. NDT Plus. 2009;2:36-39. [PMID: 25949282 DOI: 10.1093/ndtplus/sfn168] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
3 Chung MS, Han SJ. Endometriosis-Associated Angiogenesis and Anti-angiogenic Therapy for Endometriosis. Front Glob Womens Health 2022;3:856316. [DOI: 10.3389/fgwh.2022.856316] [Reference Citation Analysis]
4 Lau CML, Yu Y, Jahanmir G, Chau Y. Controlled release technology for anti-angiogenesis treatment of posterior eye diseases: Current status and challenges. Advanced Drug Delivery Reviews 2018;126:145-61. [DOI: 10.1016/j.addr.2018.03.013] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
5 Collet G, Skrzypek K, Grillon C, Matejuk A, El Hafni-Rahbi B, Lamerant-Fayel N, Kieda C. Hypoxia control to normalize pathologic angiogenesis: potential role for endothelial precursor cells and miRNAs regulation. Vascul Pharmacol. 2012;56:252-261. [PMID: 22446152 DOI: 10.1016/j.vph.2012.03.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
6 Benayoun Y, Petellat F, Leclerc O, Dost L, Dallaudière B, Reddy C, Robert PY, Salomon JL. [Current treatments for corneal neovascularization]. J Fr Ophtalmol 2015;38:996-1008. [PMID: 26522890 DOI: 10.1016/j.jfo.2015.09.006] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
7 Zayit-soudry S, Zemel E, Loewenstein A, Perlman I. SAFETY EVALUATION OF REPEATED INTRAVITREAL INJECTIONS OF BEVACIZUMAB AND RANIBIZUMAB IN RABBIT EYES. Retina 2010;30:671-81. [DOI: 10.1097/iae.0b013e3181c0858c] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
8 Morgan MA, Reuter CWM. Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias. Ann Hematol 2006;85:139-63. [DOI: 10.1007/s00277-005-0051-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
9 Davydova N, Roufail S, Streltsov VA, Stacker SA, Achen MG. The VD1 neutralizing antibody to vascular endothelial growth factor-D: binding epitope and relationship to receptor binding. J Mol Biol 2011;407:581-93. [PMID: 21315726 DOI: 10.1016/j.jmb.2011.02.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
10 Madu CO, Wang S, Madu CO, Lu Y. Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment. J Cancer 2020;11:4474-94. [PMID: 32489466 DOI: 10.7150/jca.44313] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
11 Peyman GA, Lad EM, Moshfeghi DM. Intravitreal injection of therapeutic agents. Retina. 2009;29:875-912. [PMID: 19584648 DOI: 10.1097/iae.0b013e3181a94f01] [Cited by in Crossref: 134] [Cited by in F6Publishing: 51] [Article Influence: 10.3] [Reference Citation Analysis]
12 Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? Angiogenesis. 2017;20:185-204. [PMID: 28361267 DOI: 10.1007/s10456-017-9552-y] [Cited by in Crossref: 215] [Cited by in F6Publishing: 220] [Article Influence: 43.0] [Reference Citation Analysis]
13 Bishop CV, Lee DM, Slayden OD, Li X. Intravenous neutralization of vascular endothelial growth factor reduces vascular function/permeability of the ovary and prevents development of OHSS-like symptoms in rhesus monkeys. J Ovarian Res 2017;10:41. [PMID: 28683759 DOI: 10.1186/s13048-017-0340-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
14 Redmond KL, Papafili A, Lawler M, Van Schaeybroeck S. Overcoming Resistance to Targeted Therapies in Cancer. Semin Oncol. 2015;42:896-908. [PMID: 26615134 DOI: 10.1053/j.seminoncol.2015.09.028] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
15 Srikiatkhachorn A, Kelley JF. Endothelial cells in dengue hemorrhagic fever. Antiviral Res 2014;109:160-70. [PMID: 25025934 DOI: 10.1016/j.antiviral.2014.07.005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
16 Zheng Y, Chen J, Craven M, Choi NW, Totorica S, Diaz-Santana A, Kermani P, Hempstead B, Fischbach-Teschl C, López JA, Stroock AD. In vitro microvessels for the study of angiogenesis and thrombosis. Proc Natl Acad Sci U S A 2012;109:9342-7. [PMID: 22645376 DOI: 10.1073/pnas.1201240109] [Cited by in Crossref: 601] [Cited by in F6Publishing: 526] [Article Influence: 60.1] [Reference Citation Analysis]
17 Lu J, Jackson JK, Gleave ME, Burt HM. The preparation and characterization of anti-VEGFR2 conjugated, paclitaxel-loaded PLLA or PLGA microspheres for the systemic targeting of human prostate tumors. Cancer Chemother Pharmacol 2008;61:997-1005. [DOI: 10.1007/s00280-007-0557-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
18 Chen DH, Zhang XS. Targeted therapy: resistance and re-sensitization. Chin J Cancer 2015;34:496-501. [PMID: 26370727 DOI: 10.1186/s40880-015-0047-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
19 Zhang J, Gao B, Zhang W, Qian Z, Xiang Y. Monitoring antiangiogenesis of bevacizumab in zebrafish. Drug Des Devel Ther 2018;12:2423-30. [PMID: 30122900 DOI: 10.2147/DDDT.S166330] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Ouarné M, Bouvard C, Boneva G, Mallet C, Ribeiro J, Desroches-Castan A, Soleilhac E, Tillet E, Peyruchaud O, Bailly S. BMP9, but not BMP10, acts as a quiescence factor on tumor growth, vessel normalization and metastasis in a mouse model of breast cancer. J Exp Clin Cancer Res 2018;37:209. [PMID: 30165893 DOI: 10.1186/s13046-018-0885-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
21 Pan Y, Wu Q, Qin L, Cai J, Du B. Gold nanoparticles inhibit VEGF165-induced migration and tube formation of endothelial cells via the Akt pathway. Biomed Res Int 2014;2014:418624. [PMID: 24987682 DOI: 10.1155/2014/418624] [Cited by in Crossref: 42] [Cited by in F6Publishing: 49] [Article Influence: 5.3] [Reference Citation Analysis]
22 Hurmeric V, Mumcuoglu T, Erdurman C, Kurt B, Dagli O, Durukan AH. Effect of Subconjunctival Bevacizumab (Avastin) on Experimental Corneal Neovascularization in Guinea Pigs. Cornea 2008;27:357-62. [DOI: 10.1097/ico.0b013e318160d019] [Cited by in Crossref: 31] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
23 Wen J, Matsumoto K, Taniura N, Tomioka D, Nakamura T. Inhibition of colon cancer growth and metastasis by NK4 gene repetitive delivery in mice. Biochemical and Biophysical Research Communications 2007;358:117-23. [DOI: 10.1016/j.bbrc.2007.04.098] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
24 Carbary-Ganz JL, Barton JK, Utzinger U. Quantum dots targeted to vascular endothelial growth factor receptor 2 as a contrast agent for the detection of colorectal cancer. J Biomed Opt 2014;19:086003. [PMID: 25104409 DOI: 10.1117/1.JBO.19.8.086003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
25 Batman C, Ozdamar Y. The relation between bevacizumab injection and the formation of subretinal fibrosis in diabetic patients with panretinal photocoagulation. Ophthalmic Surg Lasers Imaging 2010;41:190-5. [PMID: 20307036 DOI: 10.3928/15428877-20100303-06] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
26 Al-jandan B. Effect of antiangiogenic targeted chemotherapy on the osseointegration of titanium implants in rabbits. British Journal of Oral and Maxillofacial Surgery 2019;57:157-63. [DOI: 10.1016/j.bjoms.2019.01.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
27 Holmgren L. Horizontal gene transfer: you are what you eat. Biochem Biophys Res Commun. 2010;396:147-151. [PMID: 20494129 DOI: 10.1016/j.bbrc.2010.04.026] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
28 Schaffhauser B, Veikkola T, Strittmatter K, Antoniadis H, Alitalo K, Christofori G. Moderate antiangiogenic activity by local, transgenic expression of endostatin in Rip1Tag2 transgenic mice. Journal of Leukocyte Biology 2006;80:669-76. [DOI: 10.1189/jlb.1105644] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
29 Schiffelers RM, van der Vaart TK, Storm G. Neovascular age-related macular degeneration: opportunities for development of first-in-class biopharmaceuticals. BioDrugs 2011;25:171-89. [PMID: 21627341 DOI: 10.2165/11589330-000000000-00000] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
30 Fischbach C, Chen R, Matsumoto T, Schmelzle T, Brugge JS, Polverini PJ, Mooney DJ. Engineering tumors with 3D scaffolds. Nat Methods 2007;4:855-60. [DOI: 10.1038/nmeth1085] [Cited by in Crossref: 601] [Cited by in F6Publishing: 546] [Article Influence: 40.1] [Reference Citation Analysis]
31 Oh DH, Chun YS, Kim JC. A case of ocular benign lymphoid hyperplasia treated with bevacizumab injection. Korean J Ophthalmol 2011;25:57-9. [PMID: 21350697 DOI: 10.3341/kjo.2011.25.1.57] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
32 Minea RO, Helchowski CM, Zidovetzki SJ, Costa FK, Swenson SD, Markland FS Jr. Vicrostatin - an anti-invasive multi-integrin targeting chimeric disintegrin with tumor anti-angiogenic and pro-apoptotic activities. PLoS One 2010;5:e10929. [PMID: 20532165 DOI: 10.1371/journal.pone.0010929] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
33 Wong P, Houghton P, Kirsch DG, Finkelstein SE, Monjazeb AM, Xu-Welliver M, Dicker AP, Ahmed M, Vikram B, Teicher BA, Coleman CN, Machtay M, Curran WJ, Wang D. Combining targeted agents with modern radiotherapy in soft tissue sarcomas. J Natl Cancer Inst 2014;106:dju329. [PMID: 25326640 DOI: 10.1093/jnci/dju329] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
34 Fallah MR, Khosravi K, Hashemian MN, Beheshtnezhad AH, Rajabi MT, Gohari M. Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium. Curr Eye Res 2010;35:17-22. [PMID: 20021250 DOI: 10.3109/02713680903395273] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]
35 Durham JT, Herman IM. Microvascular modifications in diabetic retinopathy. Curr Diab Rep 2011;11:253-64. [PMID: 21611764 DOI: 10.1007/s11892-011-0204-0] [Cited by in Crossref: 119] [Cited by in F6Publishing: 113] [Article Influence: 10.8] [Reference Citation Analysis]
36 Zhang X, Wang J, Shi J, Jia X, Dang S, Wang W. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma. JAMA Netw Open 2021;4:e214846. [PMID: 33825837 DOI: 10.1001/jamanetworkopen.2021.4846] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Kankeu Fonkoua LA, Yoon HH. Rapidly Evolving Treatment Landscape for Metastatic Esophagogastric Carcinoma: Review of Recent Data. Onco Targets Ther 2021;14:4361-81. [PMID: 34385820 DOI: 10.2147/OTT.S216047] [Reference Citation Analysis]
38 Kadar T, Amir A, Cohen L, Cohen M, Sahar R, Gutman H, Horwitz V, Dachir S. Anti-VEGF Therapy (Bevacizumab) for Sulfur Mustard-Induced Corneal Neovascularization Associated with Delayed Limbal Stem Cell Deficiency in Rabbits. Current Eye Research 2013;39:439-50. [DOI: 10.3109/02713683.2013.850098] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
39 Imoukhuede PI, Popel AS. Quantitative fluorescent profiling of VEGFRs reveals tumor cell and endothelial cell heterogeneity in breast cancer xenografts. Cancer Med 2014;3:225-44. [PMID: 24449499 DOI: 10.1002/cam4.188] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
40 Mody K, Baldeo C, Bekaii-Saab T. Antiangiogenic Therapy in Colorectal Cancer. Cancer J 2018;24:165-70. [PMID: 30119079 DOI: 10.1097/PPO.0000000000000328] [Cited by in Crossref: 33] [Cited by in F6Publishing: 17] [Article Influence: 11.0] [Reference Citation Analysis]
41 Watanabe M, Boyer JL, Crystal RG. Genetic delivery of bevacizumab to suppress vascular endothelial growth factor-induced high-permeability pulmonary edema. Hum Gene Ther 2009;20:598-610. [PMID: 19254174 DOI: 10.1089/hum.2008.169] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
42 Soyama H, Miyamoto M, Matsuura H, Iwahashi H, Kakimoto S, Ishibashi H, Sakamoto T, Hada T, Suminokura J, Takano M. Rapid decrease in serum VEGF-A levels may be a worse prognostic biomarker for patients with platinum-resistant recurrent ovarian cancer treated with bevacizumab and gemcitabine. Cancer Chemother Pharmacol 2020;85:941-7. [PMID: 32279102 DOI: 10.1007/s00280-020-04070-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Liapi E, Geschwind JF. Combination of local transcatheter arterial chemoembolization and systemic anti-angiogenic therapy for unresectable hepatocellular carcinoma. Liver Cancer. 2012;1:201-215. [PMID: 24159585 DOI: 10.1159/000343835] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
44 Bequet-romero M, Ayala M, Acevedo BE, Rodríguez EG, López Ocejo O, Torrens I, Gavilondo JV. Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice. Angiogenesis 2007;10:23-34. [DOI: 10.1007/s10456-006-9062-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
45 Shintani D, Yoshida H, Yabuno A, Fujiwara K. Tolerability and Efficacy of Bevacizumab Monotherapy in Older Patients With Recurrent Ovarian Cancer. In Vivo 2020;34:1451-7. [PMID: 32354945 DOI: 10.21873/invivo.11928] [Reference Citation Analysis]
46 Gong G, Zheng Y, Kong X, Wen Z. Anti-angiogenesis Function of Ononin via Suppressing the MEK/Erk Signaling Pathway. J Nat Prod 2021;84:1755-62. [PMID: 34029083 DOI: 10.1021/acs.jnatprod.1c00008] [Reference Citation Analysis]
47 Volk LD, Flister MJ, Chihade D, Desai N, Trieu V, Ran S. Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases. Neoplasia 2011;13:327-38. [PMID: 21472137 DOI: 10.1593/neo.101490] [Cited by in Crossref: 60] [Cited by in F6Publishing: 46] [Article Influence: 5.5] [Reference Citation Analysis]
48 Chen WC, Qiu JT, Lai CH, Huang HJ, Lin CT, Chen MY, Chou HH, Huang KG, Chang TC. Outcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan. PLoS One 2017;12:e0175703. [PMID: 28467466 DOI: 10.1371/journal.pone.0175703] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
49 Kaiser RS, Gupta OP, Regillo CD, Ho AC, Fineman MS, Vander JF, McNamara JA, Brown GC. Ranibizumab for eyes previously treated with pegaptanib or bevacizumab without clinical response. Ophthalmic Surg Lasers Imaging 2012;43:13-9. [PMID: 21986085 DOI: 10.3928/15428877-20111006-01] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
50 Eleftheriou NM, Sjölund J, Bocci M, Cortez E, Lee SJ, Cunha SI, Pietras K. Compound genetically engineered mouse models of cancer reveal dual targeting of ALK1 and endoglin as a synergistic opportunity to impinge on angiogenic TGF-β signaling. Oncotarget 2016;7:84314-25. [PMID: 27741515 DOI: 10.18632/oncotarget.12604] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
51 Oladiran O, Nazir S. Bevacizumab: A Rare Cause of Nonischemic Cardiomyopathy. Case Rep Cardiol 2018;2018:1361326. [PMID: 30225147 DOI: 10.1155/2018/1361326] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
52 Chen X, Li J, Li M, Zeng M, Li T, Xiao W, Li J, Wu Q, Ke X, Luo D, Tang S, Luo Y. KH902 suppresses high glucose-induced migration and sprouting of human retinal endothelial cells by blocking VEGF and PIGF. Diabetes Obes Metab 2013;15:224-33. [DOI: 10.1111/dom.12008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
53 Merentie M, Rissanen R, Lottonen-Raikaslehto L, Huusko J, Gurzeler E, Turunen MP, Holappa L, Mäkinen P, Ylä-Herttuala S. Doxycycline modulates VEGF-A expression: Failure of doxycycline-inducible lentivirus shRNA vector to knockdown VEGF-A expression in transgenic mice. PLoS One 2018;13:e0190981. [PMID: 29351307 DOI: 10.1371/journal.pone.0190981] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
54 Aronica SM, Raiber L, Hanzly M, Kisela C. Antitumor/antiestrogenic effect of the chemokine interferon inducible protein 10 (IP-10) involves suppression of VEGF expression in mammary tissue. J Interferon Cytokine Res 2009;29:83-92. [PMID: 19014340 DOI: 10.1089/jir.2008.0034] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
55 Voronov E, Carmi Y, Apte RN. The role IL-1 in tumor-mediated angiogenesis. Front Physiol 2014;5:114. [PMID: 24734023 DOI: 10.3389/fphys.2014.00114] [Cited by in Crossref: 118] [Cited by in F6Publishing: 116] [Article Influence: 14.8] [Reference Citation Analysis]
56 Zolfaghari Saravi Z, Seyedmajidi M, Sharbatdaran M, Bijani A, Mozaffari F, Aminishakib P. VEGFR-3 Expression in Oral Lichen Planus. Asian Pac J Cancer Prev 2017;18:381-4. [PMID: 28345335 DOI: 10.22034/APJCP.2017.18.2.381] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
57 Riccardi C, Napolitano E, Platella C, Musumeci D, Melone MAB, Montesarchio D. Anti-VEGF DNA-based aptamers in cancer therapeutics and diagnostics. Med Res Rev 2021;41:464-506. [PMID: 33038031 DOI: 10.1002/med.21737] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
58 Ferreira LM, Alonso JD, Kiill CP, Ferreira NN, Buzzá HH, Martins de Godoi DR, de Britto D, Assis OBG, Seraphim TV, Borges JC, Gremião MPD. Exploiting supramolecular interactions to produce bevacizumab-loaded nanoparticles for potential mucosal delivery. European Polymer Journal 2018;103:238-50. [DOI: 10.1016/j.eurpolymj.2018.04.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
59 Lawrence JA, Akman SA, Melin SA, Case LD, Schwartz GG. Oral paricalcitol (19-nor-1,25-dihydroxyvitamin D2) in women receiving chemotherapy for metastatic breast cancer: a feasibility trial. Cancer Biol Ther 2013;14:476-80. [PMID: 23760489 DOI: 10.4161/cbt.24350] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
60 Saha S, Islam MK, Shilpi JA, Hasan S. Inhibition of VEGF: a novel mechanism to control angiogenesis by Withania somnifera's key metabolite Withaferin A. In Silico Pharmacol 2013;1:11. [PMID: 25505656 DOI: 10.1186/2193-9616-1-11] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
61 Li H. Angiogenesis in the progression from liver fibrosis to cirrhosis and hepatocelluar carcinoma. Expert Rev Gastroenterol Hepatol 2021;15:217-33. [PMID: 33131349 DOI: 10.1080/17474124.2021.1842732] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
62 Pedersen KB, Sjølie AK, Møller F. Intravitreal bevacizumab (Avastin ® ) for neovascular age-related macular degeneration in treatment-naive patients. Acta Ophthalmologica 2009;87:714-9. [DOI: 10.1111/j.1755-3768.2008.01346.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
63 Zarei Mahmudabadi A, Masoomi Karimi M, Bahabadi M, Bagheri Hoseinabadi Z, JafariSani M, Ahmadi R. Inhibition of AGS Cancer Cell Proliferation following siRNA-Mediated Downregulation of VEGFR2. Cell J 2016;18:381-8. [PMID: 27602320 DOI: 10.22074/cellj.2016.4566] [Reference Citation Analysis]
64 Pei Z, Lin D, Song X, Li H, Yao H. TLR4 signaling promotes the expression of VEGF and TGFbeta1 in human prostate epithelial PC3 cells induced by lipopolysaccharide. Cell Immunol 2008;254:20-7. [PMID: 18649875 DOI: 10.1016/j.cellimm.2008.06.007] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
65 Rozga P, Kloska D, Pawlak S, Teska-Kaminska M, Galazka M, Bukato K, Pieczykolan A, Jaworski A, Molga-Kaczmarska A, Kopacz A, Badyra B, Kachamakova-Trojanowska N, Zolnierkiewicz O, Targosz-Korecka M, Poleszak K, Szymanik M, Zerek B, Pieczykolan J, Jozkowicz A, Grochot-Przeczek A. Novel engineered TRAIL-based chimeric protein strongly inhibits tumor growth and bypasses TRAIL resistance. Int J Cancer 2020;147:1117-30. [PMID: 31863596 DOI: 10.1002/ijc.32845] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
66 Arakawa Y, Mineharu Y, Uto M, Mizowaki T. Optimal managements of elderly patients with glioblastoma. Jpn J Clin Oncol 2022:hyac075. [PMID: 35552425 DOI: 10.1093/jjco/hyac075] [Reference Citation Analysis]
67 Wright JD, Hagemann A, Rader JS, Viviano D, Gibb RK, Norris L, Mutch DG, Powell MA. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. Cancer. 2006;107:83-89. [PMID: 16736514 DOI: 10.1002/cncr.21969] [Cited by in Crossref: 105] [Cited by in F6Publishing: 91] [Article Influence: 6.6] [Reference Citation Analysis]
68 Kane SE. Cancer therapies targeted to the epidermal growth factor receptor and its family members. Expert Opinion on Therapeutic Patents 2006;16:147-64. [DOI: 10.1517/13543776.16.2.147] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
69 Borzilleri RM, Bhide RS, Barrish JC, D'Arienzo CJ, Derbin GM, Fargnoli J, Hunt JT, Jeyaseelan R Sr, Kamath A, Kukral DW, Marathe P, Mortillo S, Qian L, Tokarski JS, Wautlet BS, Zheng X, Lombardo LJ. Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2. J Med Chem 2006;49:3766-9. [PMID: 16789733 DOI: 10.1021/jm060347y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
70 Arimoto A, Uehara K, Tsuzuki T, Aiba T, Ebata T, Nagino M. Role of bevacizumab in neoadjuvant chemotherapy and its influence on microvessel density in rectal cancer. Int J Clin Oncol 2015;20:935-42. [PMID: 25788218 DOI: 10.1007/s10147-015-0818-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
71 Razavi ZS, Asgarpour K, Mahjoubin-Tehran M, Rasouli S, Khan H, Shahrzad MK, Hamblin MR, Mirzaei H. Angiogenesis-related non-coding RNAs and gastrointestinal cancer. Mol Ther Oncolytics 2021;21:220-41. [PMID: 34095461 DOI: 10.1016/j.omto.2021.04.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
72 Lee S, Go J, Rhiu S, Stulting RD, Lee M, Jang S, Lee S, Kim HJ, Chung ES, Kim S, Seo KY. Cosmetic Regional Conjunctivectomy With Postoperative Mitomycin C Application With or Without Bevacizumab Injection. American Journal of Ophthalmology 2013;156:616-622.e3. [DOI: 10.1016/j.ajo.2013.01.035] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
73 Feng B, Zhou F, Wang D, Xu Z, Yu H, Li Y. Gold nanomaterials for treatment of metastatic cancer. Sci China Chem 2016;59:984-90. [DOI: 10.1007/s11426-016-5593-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
74 Pinto MP, Badtke MM, Dudevoir ML, Harrell JC, Jacobsen BM, Horwitz KB. Vascular endothelial growth factor secreted by activated stroma enhances angiogenesis and hormone-independent growth of estrogen receptor-positive breast cancer. Cancer Res 2010;70:2655-64. [PMID: 20332242 DOI: 10.1158/0008-5472.CAN-09-4373] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
75 Chen R, Cohen AL, Colman H. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future. Curr Treat Options in Oncol 2016;17. [DOI: 10.1007/s11864-016-0418-0] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 9.8] [Reference Citation Analysis]
76 Kumari N, Saxena S, Agrawal U. Exosomal protein interactors as emerging therapeutic targets in urothelial bladder cancer. J Egypt Natl Canc Inst 2015;27:51-8. [PMID: 25726332 DOI: 10.1016/j.jnci.2015.02.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
77 Liu S, Shi W, Zhao Q, Zheng Z, Liu Z, Meng L, Dong L, Jiang X. Progress and prospect in tumor treating fields treatment of glioblastoma. Biomed Pharmacother 2021;141:111810. [PMID: 34214730 DOI: 10.1016/j.biopha.2021.111810] [Reference Citation Analysis]
78 Njah K, Chakraborty S, Qiu B, Arumugam S, Raju A, Pobbati AV, Lakshmanan M, Tergaonkar V, Thibault G, Wang X, Hong W. A Role of Agrin in Maintaining the Stability of Vascular Endothelial Growth Factor Receptor-2 during Tumor Angiogenesis. Cell Rep 2019;28:949-965.e7. [PMID: 31340156 DOI: 10.1016/j.celrep.2019.06.036] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
79 Abéngozar MA, de Frutos S, Ferreiro S, Soriano J, Perez-Martinez M, Olmeda D, Marenchino M, Cañamero M, Ortega S, Megias D, Rodriguez A, Martínez-Torrecuadrada JL. Blocking ephrinB2 with highly specific antibodies inhibits angiogenesis, lymphangiogenesis, and tumor growth. Blood 2012;119:4565-76. [PMID: 22446484 DOI: 10.1182/blood-2011-09-380006] [Cited by in Crossref: 76] [Cited by in F6Publishing: 70] [Article Influence: 7.6] [Reference Citation Analysis]
80 Kanda S, Miyata Y, Kanetake H. Current status and perspective of antiangiogenic therapy for cancer: urinary cancer. Int J Clin Oncol 2006;11:90-107. [DOI: 10.1007/s10147-006-0565-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
81 Ishii H, Afify SM, Hassan G, Salomon DS, Seno M. Cripto-1 as a Potential Target of Cancer Stem Cells for Immunotherapy. Cancers (Basel) 2021;13:2491. [PMID: 34065315 DOI: 10.3390/cancers13102491] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
82 Gehmeyr J, Maghnouj A, Tjaden J, Vorgerd M, Hahn S, Matschke V, Theis V, Theiss C. Disabling VEGF-Response of Purkinje Cells by Downregulation of KDR via miRNA-204-5p. Int J Mol Sci 2021;22:2173. [PMID: 33671638 DOI: 10.3390/ijms22042173] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Mondello P, Cuzzocrea S, Navarra M, Mian M. Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression. Oncotarget 2017;8:20394-409. [PMID: 28099912 DOI: 10.18632/oncotarget.14610] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
84 Kezeminasab S, Emamalizadeh B, Khoubnasabjafari M, Jouyban A. Exhaled Breath Condensate: A Non-Invasive Source for Tracking of Genetic and Epigenetic Alterations in Lung Diseases. Pharm Sci 2021;27:149-61. [DOI: 10.34172/ps.2020.46] [Reference Citation Analysis]
85 Tang Y, Lou J, Alpaugh RK, Robinson MK, Marks JD, Weiner LM. Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol 2007;179:2815-23. [PMID: 17709495 DOI: 10.4049/jimmunol.179.5.2815] [Cited by in Crossref: 83] [Cited by in F6Publishing: 79] [Article Influence: 5.5] [Reference Citation Analysis]
86 Piha-Paul SA, Wheler JJ, Fu S, Levenback C, Lu K, Falchook GS, Naing A, Hong DS, Tsimberidou AM, Kurzrock R. Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. Oncotarget 2014;5:1846-55. [PMID: 24742900 DOI: 10.18632/oncotarget.1834] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
87 Tai YT, Anderson KC. Antibody-based therapies in multiple myeloma. Bone Marrow Res 2011;2011:924058. [PMID: 22046572 DOI: 10.1155/2011/924058] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.0] [Reference Citation Analysis]
88 Szadai L, Velasquez E, Szeitz B, Almeida NP, Domont G, Betancourt LH, Gil J, Marko-Varga M, Oskolas H, Jánosi ÁJ, Boyano-Adánez MDC, Kemény L, Baldetorp B, Malm J, Horvatovich P, Szász AM, Németh IB, Marko-Varga G. Deep Proteomic Analysis on Biobanked Paraffine-Archived Melanoma with Prognostic/Predictive Biomarker Read-Out. Cancers (Basel) 2021;13:6105. [PMID: 34885218 DOI: 10.3390/cancers13236105] [Reference Citation Analysis]
89 Ali S, Borin TF, Piranlioglu R, Ara R, Lebedyeva I, Angara K, Achyut BR, Arbab AS, Rashid MH. Changes in the tumor microenvironment and outcome for TME-targeting therapy in glioblastoma: A pilot study. PLoS One 2021;16:e0246646. [PMID: 33544755 DOI: 10.1371/journal.pone.0246646] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Huo H, Jiang W, Sun F, Li J, Shi B. Synthesis and biological evaluation of novel steroidal pyrazole amides as highly potent anticancer agents. Steroids 2021;176:108931. [PMID: 34655595 DOI: 10.1016/j.steroids.2021.108931] [Reference Citation Analysis]
91 Nihei S, Asaka J, Takahashi H, Kudo K. Bevacizumab Increases Endothelin-1 Production via Forkhead Box Protein O1 in Human Glomerular Microvascular Endothelial Cells In Vitro. Int J Nephrol 2021;2021:8381115. [PMID: 34912580 DOI: 10.1155/2021/8381115] [Reference Citation Analysis]
92 Ohnuki H, Tosato G. Characterization of Semaphorin 6A-Mediated Effects on Angiogenesis Through Regulation of VEGF Signaling. Methods Mol Biol 2017;1493:345-61. [PMID: 27787863 DOI: 10.1007/978-1-4939-6448-2_25] [Reference Citation Analysis]
93 Fallah Tafti MR, Khosravifard K, Mohammadpour M, Hashemian MN, Kiarudi MY. Efficacy of Intralesional Bevacizumab Injection in Decreasing Pterygium Size. Cornea 2011;30:127-9. [DOI: 10.1097/ico.0b013e3181e16d67] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
94 Zhang S, Ji Y, Liu X, Lu X, Su W, Zhang D, Hao F, Yi F, Guo L, Li X, Zheng Y. Podocyte-specific VEGF down-regulation and pathophysiological development. IUBMB Life 2010;62:677-83. [PMID: 20827751 DOI: 10.1002/iub.368] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
95 Sahebnasagh A, Avan R, Saghafi F, Mojtahedzadeh M, Sadremomtaz A, Arasteh O, Tanzifi A, Faramarzi F, Negarandeh R, Safdari M, Khataminia M, Rezai Ghaleno H, Habtemariam S, Khoshi A. Pharmacological treatments of COVID-19. Pharmacol Rep 2020;72:1446-78. [PMID: 32816200 DOI: 10.1007/s43440-020-00152-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 5.5] [Reference Citation Analysis]
96 Schraermeyer U, Julien S. Effects of bevacizumab in retina and choroid after intravitreal injection into monkey eyes. Expert Opin Biol Ther 2013;13:157-67. [PMID: 23190450 DOI: 10.1517/14712598.2012.748741] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
97 Mitchell JM, Flight RM, Moseley HNB. Untargeted Lipidomics of Non-Small Cell Lung Carcinoma Demonstrates Differentially Abundant Lipid Classes in Cancer vs. Non-Cancer Tissue. Metabolites 2021;11:740. [PMID: 34822397 DOI: 10.3390/metabo11110740] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Merkouris S, Barde YA, Binley KE, Allen ND, Stepanov AV, Wu NC, Grande G, Lin CW, Li M, Nan X, Chacon-Fernandez P, DiStefano PS, Lindsay RM, Lerner RA, Xie J. Fully human agonist antibodies to TrkB using autocrine cell-based selection from a combinatorial antibody library. Proc Natl Acad Sci U S A 2018;115:E7023-32. [PMID: 29987039 DOI: 10.1073/pnas.1806660115] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
99 Kim DG, Jin Y, Jin J, Yang H, Joo KM, Lee WS, Shim SR, Kim SW, Yoo J, Lee SH, Yoo JS, Nam DH. Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis. MAbs 2015;7:1195-204. [PMID: 26325365 DOI: 10.1080/19420862.2015.1086854] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
100 Fakih M. The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer. Expert Rev Anticancer Ther. 2013;13:427-438. [PMID: 23432698 DOI: 10.1586/era.13.20] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
101 Weisshardt P, Trarbach T, Dürig J, Paul A, Reis H, Tilki D, Miroschnik I, Ergün S, Klein D. Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab. Histochem Cell Biol 2012;137:391-401. [PMID: 22193946 DOI: 10.1007/s00418-011-0898-8] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]
102 Gupta D, Illingworth C. Treatments for corneal neovascularization: a review. Cornea 2011;30:927-38. [PMID: 21389854 DOI: 10.1097/ICO.0b013e318201405a] [Cited by in Crossref: 67] [Cited by in F6Publishing: 35] [Article Influence: 6.1] [Reference Citation Analysis]
103 Shahin MM, Elbendary AM, Elwan MM. Intraoperative Subconjunctival Bevacizumab as an Adjunctive Treatment in Primary Pterygium: A Preliminary Report. Ophthalmic Surg Lasers Imaging 2012;43:459-66. [DOI: 10.3928/15428877-20120802-02] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
104 Farha S, Asosingh K, Laskowski D, Licina L, Sekiguchi H, Losordo DW, Dweik RA, Wiedemann HP, Erzurum SC. Pulmonary gas transfer related to markers of angiogenesis during the menstrual cycle. J Appl Physiol (1985) 2007;103:1789-95. [PMID: 17717117 DOI: 10.1152/japplphysiol.00614.2007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
105 Lee DH, Ryu HW, Won HR, Kwon SH. Advances in epigenetic glioblastoma therapy. Oncotarget 2017;8:18577-89. [PMID: 28099914 DOI: 10.18632/oncotarget.14612] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 8.6] [Reference Citation Analysis]
106 Fan QW, Weiss WA. Chemical genetic approaches to the development of cancer therapeutics. Curr Opin Genet Dev 2006;16:85-91. [PMID: 16359858 DOI: 10.1016/j.gde.2005.12.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
107 Patil R, Wong CW, Michelet F, Teo K, Ting D, Tsai A, Cheung CMG, Wong TY. Angiogenesis-Based Therapies for Eye Diseases. In: Mehta JL, Mathur P, Dhalla NS, editors. Biochemical Basis and Therapeutic Implications of Angiogenesis. Cham: Springer International Publishing; 2017. pp. 259-97. [DOI: 10.1007/978-3-319-61115-0_12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
108 Tortorella S, Karagiannis TC. Transferrin Receptor-Mediated Endocytosis: A Useful Target for Cancer Therapy. J Membrane Biol 2014;247:291-307. [DOI: 10.1007/s00232-014-9637-0] [Cited by in Crossref: 158] [Cited by in F6Publishing: 143] [Article Influence: 19.8] [Reference Citation Analysis]
109 Lim DK, Wylie RG, Langer R, Kohane DS. Selective binding of C-6 OH sulfated hyaluronic acid to the angiogenic isoform of VEGF(165). Biomaterials 2016;77:130-8. [PMID: 26588795 DOI: 10.1016/j.biomaterials.2015.10.074] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
110 Krishnan H, Miller WT, Goldberg GS. SRC points the way to biomarkers and chemotherapeutic targets. Genes Cancer 2012;3:426-35. [PMID: 23226580 DOI: 10.1177/1947601912458583] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
111 Heiduschka P, Julien S, Hofmeister S, Bartz-Schmidt KU, Schraermeyer U. Bevacizumab (avastin) does not harm retinal function after intravitreal injection as shown by electroretinography in adult mice. Retina 2008;28:46-55. [PMID: 18185137 DOI: 10.1097/IAE.0b013e31815e9368] [Cited by in Crossref: 28] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
112 Di J, Xie F, Xu Y. When liposomes met antibodies: Drug delivery and beyond. Adv Drug Deliv Rev 2020;154-155:151-62. [PMID: 32926944 DOI: 10.1016/j.addr.2020.09.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
113 Dinc E, Yildirim O, Ayaz L, Ozcan T, Yilmaz SN. Effects of intravitreal injection of bevacizumab on nitric oxide levels. Eye (Lond) 2015;29:436-42. [PMID: 25523201 DOI: 10.1038/eye.2014.297] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
114 Joshi S. Targeting the Tumor Microenvironment in Neuroblastoma: Recent Advances and Future Directions. Cancers (Basel) 2020;12:E2057. [PMID: 32722460 DOI: 10.3390/cancers12082057] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
115 Ilie MD, Vasiljevic A, Raverot G, Bertolino P. The Microenvironment of Pituitary Tumors-Biological and Therapeutic Implications. Cancers (Basel) 2019;11:E1605. [PMID: 31640258 DOI: 10.3390/cancers11101605] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
116 Moudgil R, Yeh ET. Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond. Can J Cardiol 2016;32:863-870.e5. [PMID: 27117975 DOI: 10.1016/j.cjca.2016.01.027] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
117 Garofalo A, Farce A, Ravez S, Lemoine A, Six P, Chavatte P, Goossens L, Depreux P. Synthesis and structure-activity relationships of (aryloxy)quinazoline ureas as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors. J Med Chem 2012;55:1189-204. [PMID: 22229669 DOI: 10.1021/jm2013453] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 4.5] [Reference Citation Analysis]
118 Morera Y, Bequet-Romero M, Ayala M, Velazco JC, Pérez PP, Alba JS, Ancizar J, Rodríguez M, Cosme K, Gavilondo JV. Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates. Vaccine 2010;28:3453-61. [PMID: 20197134 DOI: 10.1016/j.vaccine.2010.02.069] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
119 Yamasaki F, Kolakshyapati M, Takano M, Yonezawa U, Nishibuchi I, Imano N, Taguchi A, Onishi S, Amatya VJ, Takeshima Y, Nagata Y, Kurisu K, Sugiyama K. Effect of bevacizumab against cystic components of brain tumors. Cancer Med 2019;8:6519-27. [PMID: 31498567 DOI: 10.1002/cam4.2537] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
120 Ozsutcu M, Ayintap E, Akkan JC, Koytak A, Aras C. Repeated bevacizumab injections versus mitomycin C in rotational conjunctival flap for prevention of pterygium recurrence. Indian J Ophthalmol 2014;62:407-11. [PMID: 24178405 DOI: 10.4103/0301-4738.120220] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
121 Fani M, Bouziotis P, Harris AL, Psimadas D, Gourni E, Loudos G, Varvarigou AD, Maecke HR. 177 Lu-labeled-VG76e monoclonal antibody in tumor angiogenesis: A comparative study using DOTA and DTPA chelating systems. Radiochimica Acta 2007;95:351-7. [DOI: 10.1524/ract.2007.95.6.351] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
122 Ricci AG, Olivares CN, Bilotas MA, Meresman GF, Barañao RI. Effect of Vascular Endothelial Growth Factor Inhibition on Endometrial Implant Development in a Murine Model of Endometriosis. Reprod Sci 2011;18:614-22. [DOI: 10.1177/1933719110395406] [Cited by in Crossref: 67] [Cited by in F6Publishing: 65] [Article Influence: 6.1] [Reference Citation Analysis]
123 Pasquier J, Ghiabi P, Chouchane L, Razzouk K, Rafii S, Rafii A. Angiocrine endothelium: from physiology to cancer. J Transl Med 2020;18:52. [PMID: 32014047 DOI: 10.1186/s12967-020-02244-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
124 Paderi J, Prestwich GD, Panitch A, Boone T, Stuart K. Glycan Therapeutics: Resurrecting an Almost Pharma‐Forgotten Drug Class. Adv Therap 2018;1:1800082. [DOI: 10.1002/adtp.201800082] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
125 Madhusudan S, Ganesan TS. Tyrosine kinase inhibitors and cancer therapy. Recent Results Cancer Res 2007;172:25-44. [PMID: 17607934 DOI: 10.1007/978-3-540-31209-3_3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
126 Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, Satyamurthy N, Pope W, Lai A, Phelps ME, Cloughesy T. Predicting Treatment Response of Malignant Gliomas to Bevacizumab and Irinotecan by Imaging Proliferation With [ 18 F] Fluorothymidine Positron Emission Tomography: A Pilot Study. JCO 2007;25:4714-21. [DOI: 10.1200/jco.2006.10.5825] [Cited by in Crossref: 319] [Cited by in F6Publishing: 135] [Article Influence: 21.3] [Reference Citation Analysis]
127 Jun JH, Sohn WJ, Lee Y, Kim JY. Effects of anti-vascular endothelial growth factor monoclonal antibody (bevacizumab) on lens epithelial cells. Clin Ophthalmol 2016;10:1167-74. [PMID: 27418802 DOI: 10.2147/OPTH.S103443] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
128 Ballangrud AM, Lymberis S, Thakur SB, Karimi S, Huang W, Abrey LE, Beal K, Iwamoto FM, Brennan C, Gutin PH, Chang J. Magnetic resonance spectroscopy imaging in radiotherapy planning for recurrent glioma. Med Phys 2011;38:2724-30. [PMID: 21776809 DOI: 10.1118/1.3574884] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
129 Croci DO, Mendez-huergo SP, Cerliani JP, Rabinovich GA. Immune-Mediated and Hypoxia-Regulated Programs: Accomplices in Resistance to Anti-angiogenic Therapies. In: Mandalà M, Romano E, editors. Mechanisms of Drug Resistance in Cancer Therapy. Cham: Springer International Publishing; 2018. pp. 31-61. [DOI: 10.1007/164_2017_29] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
130 Fan CH, Ting CY, Liu HL, Huang CY, Hsieh HY, Yen TC, Wei KC, Yeh CK. Antiangiogenic-targeting drug-loaded microbubbles combined with focused ultrasound for glioma treatment. Biomaterials 2013;34:2142-55. [PMID: 23246066 DOI: 10.1016/j.biomaterials.2012.11.048] [Cited by in Crossref: 92] [Cited by in F6Publishing: 82] [Article Influence: 9.2] [Reference Citation Analysis]
131 Calvani M, Bianchini F, Taddei ML, Becatti M, Giannoni E, Chiarugi P, Calorini L. Etoposide-Bevacizumab a new strategy against human melanoma cells expressing stem-like traits. Oncotarget 2016;7:51138-49. [PMID: 27303923 DOI: 10.18632/oncotarget.9939] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
132 Nissim Ben Efraim AH, Levi-Schaffer F. Tissue remodeling and angiogenesis in asthma: the role of the eosinophil. Ther Adv Respir Dis 2008;2:163-71. [PMID: 19124368 DOI: 10.1177/1753465808092281] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
133 Mehdizadeh M, Fattahi F, Eghtedari M, Nowroozzadeh MH, Toosi F. The role of intravitreal bevacizumab in experimental posterior penetrating eye injury. Retina 2011;31:154-60. [PMID: 20838359 DOI: 10.1097/IAE.0b013e3181e096f3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
134 Dutta P, Dhandapani S, Kumar N, Gupta P, Ahuja C, Mukherjee KK. Bevacizumab for Radiation Induced Optic Neuritis Among Aggressive Residual/Recurrent Suprasellar Tumors: More Than a Mere Antineoplastic Effect. World Neurosurgery 2017;107:1044.e5-1044.e10. [DOI: 10.1016/j.wneu.2017.07.111] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
135 Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Geist C, Dahlbom M, Silverman DH, Satyamurthy N, Phelps ME, Chen W. 3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med 2012;53:29-36. [PMID: 22159180 DOI: 10.2967/jnumed.111.092387] [Cited by in Crossref: 96] [Cited by in F6Publishing: 91] [Article Influence: 8.7] [Reference Citation Analysis]
136 Zafar A, Wang W, Liu G, Wang X, Xian W, McKeon F, Foster J, Zhou J, Zhang R. Molecular targeting therapies for neuroblastoma: Progress and challenges. Med Res Rev 2021;41:961-1021. [PMID: 33155698 DOI: 10.1002/med.21750] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
137 Boland W, Bebb G. The emerging role of nimotuzumab in the treatment of non-small cell lung cancer. Biologics 2010;4:289-98. [PMID: 21116327 DOI: 10.2147/BTT.S8617] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
138 Rivera L, Pandika M, Bergers G. Escape mechanisms from antiangiogenic therapy: an immune cell's perspective. Adv Exp Med Biol 2014;772:83-99. [PMID: 24272355 DOI: 10.1007/978-1-4614-5915-6_4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
139 Arjumand W, Asiaf A, Ahmad ST. Noncoding RNAs in DNA Damage Response: Opportunities for Cancer Therapeutics. Methods Mol Biol 2018;1699:3-21. [PMID: 29086365 DOI: 10.1007/978-1-4939-7435-1_1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
140 Ahmed F, Onwumeh-Okwundu J, Yukselen Z, Endaya Coronel MK, Zaidi M, Guntipalli P, Garimella V, Gudapati S, Mezidor MD, Andrews K, Mouchli M, Shahini E. Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review. World J Gastrointest Oncol 2021; 13(11): 1813-1832 [PMID: 34853653 DOI: 10.4251/wjgo.v13.i11.1813] [Reference Citation Analysis]
141 Sivaprasad S, Hykin P. What is new in the management of wet age-related macular degeneration? Br Med Bull 2013;105:201-11. [PMID: 23393060 DOI: 10.1093/bmb/ldt004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
142 Carbary-Ganz JL, Welge WA, Barton JK, Utzinger U. In vivo molecular imaging of colorectal cancer using quantum dots targeted to vascular endothelial growth factor receptor 2 and optical coherence tomography/laser-induced fluorescence dual-modality imaging. J Biomed Opt 2015;20:096015. [PMID: 26397238 DOI: 10.1117/1.JBO.20.9.096015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
143 Guo Y, Wang S, Hoot DR, Clinton SK. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones. J Nutr Biochem 2007;18:408-17. [PMID: 17142033 DOI: 10.1016/j.jnutbio.2006.08.006] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 4.3] [Reference Citation Analysis]
144 Doloff JC, Chen CS, Waxman DJ. Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2. Mol Cancer 2014;13:158. [PMID: 24965046 DOI: 10.1186/1476-4598-13-158] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
145 Qiao F, Yin Y, Shen Y, Wang S, Sha S, Wu X, Lu A, Xu C, Zhang W, Zhu H. Synthesis, molecular modeling, and biological evaluation of quinazoline derivatives containing the 1,3,4-oxadiazole scaffold as novel inhibitors of VEGFR2. RSC Adv 2015;5:19914-23. [DOI: 10.1039/c4ra11780h] [Cited by in Crossref: 5] [Article Influence: 0.7] [Reference Citation Analysis]
146 Chang JH, Garg NK, Lunde E, Han KY, Jain S, Azar DT. Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol. 2012;57:415-429. [PMID: 22898649 DOI: 10.1016/j.survophthal.2012.01.007] [Cited by in Crossref: 201] [Cited by in F6Publishing: 192] [Article Influence: 20.1] [Reference Citation Analysis]
147 Enseleit F, Michels S, Ruschitzka F. Anti-VEGF Therapies and Blood Pressure: More Than Meets the Eye. Current Science Inc 2010;12:33-8. [DOI: 10.1007/s11906-009-0082-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
148 Haniff HS, Knerr L, Liu X, Crynen G, Boström J, Abegg D, Adibekian A, Lekah E, Wang KW, Cameron MD, Yildirim I, Lemurell M, Disney MD. Design of a small molecule that stimulates vascular endothelial growth factor A enabled by screening RNA fold-small molecule interactions. Nat Chem 2020;12:952-61. [PMID: 32839603 DOI: 10.1038/s41557-020-0514-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
149 Batman C, Ozdamar Y. The effect of bevacizumab for anterior segment neovascularization after silicone oil removal in eyes with previous vitreoretinal surgery. Eye (Lond) 2010;24:1243-6. [PMID: 20019762 DOI: 10.1038/eye.2009.304] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
150 Lau D, Magill ST, Aghi MK. Molecularly targeted therapies for recurrent glioblastoma: current and future targets. Neurosurg Focus 2014;37:E15. [PMID: 25434384 DOI: 10.3171/2014.9.FOCUS14519] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
151 Yu JE, Yeo IJ, Son DJ, Yun J, Han SB, Hong JT. Anti-Chi3L1 antibody suppresses lung tumor growth and metastasis through inhibition of M2 polarization. Mol Oncol 2021. [PMID: 34861103 DOI: 10.1002/1878-0261.13152] [Reference Citation Analysis]
152 Bruno JG, Carrillo MP, Crowell R. Preliminary development of DNA aptamer-Fc conjugate opsonins. J Biomed Mater Res A 2009;90:1152-61. [PMID: 18671260 DOI: 10.1002/jbm.a.32182] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
153 Ebrahimizadeh W, Mousavi Gargari SLM, Javidan Z, Rajabibazl M. Production of Novel VHH Nanobody Inhibiting Angiogenesis by Targeting Binding Site of VEGF. Appl Biochem Biotechnol 2015;176:1985-95. [DOI: 10.1007/s12010-015-1695-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
154 Ng DS, Kwok AK, Chan CW. Anti-vascular endothelial growth factor for myopic choroidal neovascularization. Clin Exp Ophthalmol 2012;40:e98-e110. [PMID: 21902785 DOI: 10.1111/j.1442-9071.2011.02684.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
155 Thoreau F, Vanwonterghem L, Henry M, Coll JL, Boturyn D. Design of RGD-ATWLPPR peptide conjugates for the dual targeting of αVβ3 integrin and neuropilin-1. Org Biomol Chem 2018;16:4101-7. [PMID: 29774910 DOI: 10.1039/c8ob00669e] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
156 Zhu N, Weng S, Wang J, Chen J, Yu L, Fang X, Yuan Y. Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors. J Cancer Res Clin Oncol 2019;145:3021-36. [PMID: 31617075 DOI: 10.1007/s00432-019-03044-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
157 Wang Z, Liu G, Zheng H, Chen X. Rigid nanoparticle-based delivery of anti-cancer siRNA: challenges and opportunities. Biotechnol Adv 2014;32:831-43. [PMID: 24013011 DOI: 10.1016/j.biotechadv.2013.08.020] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
158 Shen F, Mao L, Zhu W, Lawton MT, Pechan P, Colosi P, Wu Z, Scaria A, Su H. Inhibition of pathological brain angiogenesis through systemic delivery of AAV vector expressing soluble FLT1. Gene Ther 2015;22:893-900. [PMID: 26090874 DOI: 10.1038/gt.2015.57] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
159 Shi C, Gao F, Gao X, Liu Y. A novel anti-VEGF165 monoclonal antibody-conjugated liposomal nanocarrier system: physical characterization and cellular uptake evaluation in vitro and in vivo. Biomed Pharmacother. 2015;69:191-200. [PMID: 25661357 DOI: 10.1016/j.biopha.2014.11.025] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
160 Yeung SN, Lichtinger A, Kim P, Amiran MD, Slomovic AR. Combined use of subconjunctival and intracorneal bevacizumab injection for corneal neovascularization. Cornea 2011;30:1110-4. [PMID: 21673570 DOI: 10.1097/ICO.0b013e31821379aa] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
161 Economopoulou P, Kotsakis A, Kapiris I, Kentepozidis N. Cancer therapy and cardiovascular risk: focus on bevacizumab. Cancer Manag Res 2015;7:133-43. [PMID: 26082660 DOI: 10.2147/CMAR.S77400] [Cited by in Crossref: 43] [Cited by in F6Publishing: 20] [Article Influence: 6.1] [Reference Citation Analysis]
162 Vicari D, Foy KC, Liotta EM, Kaumaya PT. Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways. J Biol Chem 2011;286:13612-25. [PMID: 21321115 DOI: 10.1074/jbc.M110.216812] [Cited by in Crossref: 50] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
163 Zhu Q, Ziemssen F, Henke-Fahle S, Tatar O, Szurman P, Aisenbrey S, Schneiderhan-Marra N, Xu X;  Tübingen Bevacizumab Study Group; Grisanti S. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization.Ophthalmology. 2008;115:1750-1755, 1755.e1. [PMID: 18708261 DOI: 10.1016/j.ophtha.2008.04.023] [Cited by in Crossref: 101] [Cited by in F6Publishing: 104] [Article Influence: 7.2] [Reference Citation Analysis]
164 Kline CL, El-Deiry WS. Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. Pharmaceuticals (Basel) 2013;6:988-1038. [PMID: 24276379 DOI: 10.3390/ph6080988] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
165 Yoshida H, Yabuno A, Fujiwara K. Critical appraisal of bevacizumab in the treatment of ovarian cancer. Drug Des Devel Ther 2015;9:2351-8. [PMID: 25960638 DOI: 10.2147/DDDT.S83275] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
166 Geitzenauer W, Michels S, Prager F, Rosenfeld PJ, Kornek G, Vormittag L, Schmidt-Erfurth U. Comparison of 2.5 mg/kg and 5 mg/kg systemic bevacizumab in neovascular age-related macular degeneration: twenty-four week results of an uncontrolled, prospective cohort study. Retina 2008;28:1375-86. [PMID: 18784625 DOI: 10.1097/IAE.0b013e3181863f96] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
167 Volk LD, Flister MJ, Bivens CM, Stutzman A, Desai N, Trieu V, Ran S. Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy. Neoplasia 2008;10:613-23. [PMID: 18516298 DOI: 10.1593/neo.08302] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 4.0] [Reference Citation Analysis]
168 Roy S, Pan Z, Pal S. A Fokker-Planck feedback control framework for optimal personalized therapies in colon cancer-induced angiogenesis. J Math Biol 2022;84:23. [PMID: 35212794 DOI: 10.1007/s00285-022-01725-3] [Reference Citation Analysis]
169 Yildiz BK, Ozdek S, Demirci U, Ceylanoglu KS, Ozmen MC, Baykara M, Buyukberber S, Coskun U, Benekli M. Functional and morphological effects of systemic bevacizumab on cancer patients' eyes. Optom Vis Sci 2015;92:102-6. [PMID: 25360703 DOI: 10.1097/OPX.0000000000000430] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
170 Emami-Shahri N, Hagemann T. Resistance--the true face of biological defiance. Rheumatology (Oxford) 2012;51:413-22. [PMID: 22109797 DOI: 10.1093/rheumatology/ker326] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
171 Li F, Hurley B, Liu Y, Leonard B, Griffith M. Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration. Open Ophthalmol J 2012;6:54-8. [PMID: 22798970 DOI: 10.2174/1874364101206010054] [Cited by in Crossref: 64] [Cited by in F6Publishing: 59] [Article Influence: 6.4] [Reference Citation Analysis]
172 Parker MW, Guo HF, Li X, Linkugel AD, Vander Kooi CW. Function of members of the neuropilin family as essential pleiotropic cell surface receptors. Biochemistry. 2012;51:9437-9446. [PMID: 23116416 DOI: 10.1021/bi3012143] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 5.2] [Reference Citation Analysis]
173 Zhu W, Ou Y, Li Y, Xiao R, Shu M, Zhou Y, Xie J, He S, Qiu P, Yan G. A Small-Molecule Triptolide Suppresses Angiogenesis and Invasion of Human Anaplastic Thyroid Carcinoma Cells via Down-Regulation of the Nuclear Factor-κB Pathway. Mol Pharmacol 2009;75:812-9. [DOI: 10.1124/mol.108.052605] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 4.0] [Reference Citation Analysis]
174 Moccia F, Riccardi C, Musumeci D, Leone S, Oliva R, Petraccone L, Montesarchio D. Insights into the G-rich VEGF-binding aptamer V7t1: when two G-quadruplexes are better than one! Nucleic Acids Res 2019;47:8318-31. [PMID: 31276595 DOI: 10.1093/nar/gkz589] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
175 Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603. [PMID: 18650835 DOI: 10.1038/nrc2442] [Cited by in Crossref: 1958] [Cited by in F6Publishing: 1859] [Article Influence: 139.9] [Reference Citation Analysis]
176 Rosenberg JB, Hicks MJ, De BP, Pagovich O, Frenk E, Janda KD, Wee S, Koob GF, Hackett NR, Kaminsky SM, Worgall S, Tignor N, Mezey JG, Crystal RG. AAVrh.10-mediated expression of an anti-cocaine antibody mediates persistent passive immunization that suppresses cocaine-induced behavior. Hum Gene Ther 2012;23:451-9. [PMID: 22486244 DOI: 10.1089/hum.2011.178] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
177 Abd-Rabou AA, Ahmed HH. Bevacizumab and CCR2 Inhibitor Nanoparticles Induce Cytotoxicity-Mediated Apoptosis in Doxorubicin-Treated Hepatic and Non-Small Lung Cancer Cells. Asian Pac J Cancer Prev 2019;20:2225-38. [PMID: 31350989 DOI: 10.31557/APJCP.2019.20.7.2225] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
178 Nicosia RF. The aortic ring model of angiogenesis: a quarter century of search and discovery. J Cell Mol Med. 2009;13:4113-4136. [PMID: 19725916 DOI: 10.1111/j.1582-4934.2009.00891.x] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 5.5] [Reference Citation Analysis]
179 Sharma N, Kaur M, Agarwal T, Sangwan VS, Vajpayee RB. Treatment of acute ocular chemical burns. Surv Ophthalmol. 2018;63:214-235. [PMID: 28935121 DOI: 10.1016/j.survophthal.2017.09.005] [Cited by in Crossref: 51] [Cited by in F6Publishing: 39] [Article Influence: 10.2] [Reference Citation Analysis]
180 Kazemi-Lomedasht F, Behdani M, Pooshang Bagheri K, Habibi Anbouhi M, Abolhassani M, Khanahmad H, Shahbazzadeh D, Mirzahoseini H. Expression and purification of functional human vascular endothelial growth factor-a121; the most important angiogenesis factor. Adv Pharm Bull 2014;4:323-8. [PMID: 25436186 DOI: 10.5681/apb.2014.047] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
181 Qiu C, Arzhantsev S. Secondary structure assessment of formulated bevacizumab in the presence of SDS by deep ultraviolet resonance Raman (DUVRR) spectroscopy. Analytical Biochemistry 2018;555:26-32. [DOI: 10.1016/j.ab.2018.06.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
182 Imoukhuede PI, Popel AS. Quantification and cell-to-cell variation of vascular endothelial growth factor receptors. Exp Cell Res 2011;317:955-65. [PMID: 21185287 DOI: 10.1016/j.yexcr.2010.12.014] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 5.9] [Reference Citation Analysis]
183 Chao WR, Amin K, Shi Y, Hobbs P, Tanabe M, Tanga M, Jong L, Collins N, Peters R, Laderoute K, Dinh D, Yean D, Hou C, Sato B, Alt C, Sambucetti L. SR16388: a steroidal antiangiogenic agent with potent inhibitory effect on tumor growth in vivo. Angiogenesis 2011;14:1-16. [PMID: 21104121 DOI: 10.1007/s10456-010-9191-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
184 Jafari Sani M, Yazdi F, Masoomi Karimi M, Alizadeh J, Rahmati M, Zarei Mahmudabadi A. The siRNA-Mediated Down-Regulation of Vascular Endothelial Growth Factor Receptor1. Iran Red Crescent Med J 2016;18:e23418. [PMID: 27275397 DOI: 10.5812/ircmj.23418] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
185 Iturriaga-Goyon E, Buentello-Volante B, Magaña-Guerrero FS, Garfias Y. Future Perspectives of Therapeutic, Diagnostic and Prognostic Aptamers in Eye Pathological Angiogenesis. Cells 2021;10:1455. [PMID: 34200613 DOI: 10.3390/cells10061455] [Reference Citation Analysis]
186 Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW, Gonzalez S, Feuer WJ, Lin RC, Lalwani GA. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 2006;26:495-511. [PMID: 16770255 DOI: 10.1097/01.iae.0000225766.75009.3a] [Cited by in Crossref: 337] [Cited by in F6Publishing: 307] [Article Influence: 21.1] [Reference Citation Analysis]
187 Harooni H, Reddy V, Root T, Ambati B. Bevacizumab for graft rejection. Ophthalmology 2007;114:1950. [PMID: 17908597 DOI: 10.1016/j.ophtha.2007.05.016] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
188 Lee ALZ, Ng VWL, Gao S, Hedrick JL, Yang YY. Injectable Biodegradable Hydrogels from Vitamin D-Functionalized Polycarbonates for the Delivery of Avastin with Enhanced Therapeutic Efficiency against Metastatic Colorectal Cancer. Biomacromolecules 2015;16:465-75. [DOI: 10.1021/bm5015206] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 5.9] [Reference Citation Analysis]
189 Moshfeghi AA, Rosenfeld PJ, Puliafito CA, Michels S, Marcus EN, Lenchus JD, Venkatraman AS. Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular Degeneration. Ophthalmology 2006;113:2002-2011.e2. [DOI: 10.1016/j.ophtha.2006.05.070] [Cited by in Crossref: 127] [Cited by in F6Publishing: 115] [Article Influence: 7.9] [Reference Citation Analysis]
190 Klupp F, Sass M, Bergmann F, Khajeh E, Ghamarnejad O, Hassenpflug M, Mehrabi A, Kulu Y. Impact of EGFR and EGFR ligand expression on treatment response in patients with metastatic colorectal cancer. Oncol Lett 2021;21:448. [PMID: 33868486 DOI: 10.3892/ol.2021.12709] [Reference Citation Analysis]
191 Altmann KH, Memmert K. Epothilones as lead structures for new anticancer drugs--pharmacology, fermentation, and structure-activity-relationships. Prog Drug Res 2008;66:273, 275-334. [PMID: 18416309 DOI: 10.1007/978-3-7643-8595-8_6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
192 Zhao YY, Xue C, Jiang W, Zhao HY, Huang Y, Feenstra K, Resau JH, Qian CN, Zhang L. Predictive value of intratumoral microvascular density in patients with advanced non-small cell lung cancer receiving chemotherapy plus bevacizumab. J Thorac Oncol 2012;7:71-5. [PMID: 22011670 DOI: 10.1097/JTO.0b013e31823085f4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
193 Huang S, Hsieh Y, Chen C, Chen C, Sung W, Chou M, Chen S. Automatic Disulfide Bond Assignment Using a 1 Ion Screening by Mass Spectrometry for Structural Characterization of Protein Pharmaceuticals. Anal Chem 2012;84:4900-6. [DOI: 10.1021/ac3005007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
194 Ahadi M, Ghasemian H, Behdani M, Kazemi-lomedasht F. Oligoclonal selection of nanobodies targeting vascular endothelial growth factor. Journal of Immunotoxicology 2019;16:34-42. [DOI: 10.1080/1547691x.2018.1526234] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
195 Yanagisawa H, Sugimoto M, Miyashita T. Mathematical simulation of tumour angiogenesis: angiopoietin balance is a key factor in vessel growth and regression. Sci Rep 2021;11:419. [PMID: 33432093 DOI: 10.1038/s41598-020-79824-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
196 Braghiroli MI, Riechelmann RP, Sabbaga J, Hoff PM. Do We Need another Antiangiogenesis Agent for Colorectal Cancer: are Bevacizumab and Aflibercept the Same? Curr Colorectal Cancer Rep 2013;9:317-25. [DOI: 10.1007/s11888-013-0187-0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
197 Lanza GM, Caruthers SD, Winter PM, Hughes MS, Schmieder AH, Hu G, Wickline SA. Angiogenesis imaging with vascular-constrained particles: the why and how. Eur J Nucl Med Mol Imaging. 2010;37 Suppl 1:S114-S126. [PMID: 20617434 DOI: 10.1007/s00259-010-1502-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
198 E G, Cao Y, Bhattacharya S, Dutta S, Wang E, Mukhopadhyay D. Endogenous vascular endothelial growth factor-A (VEGF-A) maintains endothelial cell homeostasis by regulating VEGF receptor-2 transcription. J Biol Chem 2012;287:3029-41. [PMID: 22167188 DOI: 10.1074/jbc.M111.293985] [Cited by in Crossref: 30] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
199 Liu X, Kambrick S, Fu S, Naing A, Subbiah V, Blumenschein GR, Glisson BS, Kies MS, Tsimberidou AM, Wheler JJ, Zinner RG, Hong DS, Kurzrock R, Piha-Paul SA. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget 2016;7:23227-38. [PMID: 26933802 DOI: 10.18632/oncotarget.7594] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
200 Ziemssen F, Grisanti S, Bartz-Schmidt KU, Spitzer MS. Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence? Drugs Aging 2009;26:295-320. [PMID: 19476398 DOI: 10.2165/00002512-200926040-00002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
201 Lakatos G, Tulassay Z. [Antiangiogenic therapy for gastrointestinal tumors]. Orv Hetil 2008;149:2317-24. [PMID: 19042183 DOI: 10.1556/OH.2008.28496] [Reference Citation Analysis]
202 Gautam M, Poudel K, Yong CS, Kim JO. Prussian blue nanoparticles: Synthesis, surface modification, and application in cancer treatment. Int J Pharm 2018;549:31-49. [PMID: 30053487 DOI: 10.1016/j.ijpharm.2018.07.055] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 9.8] [Reference Citation Analysis]
203 Lee JJ, Chu E. Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer. 2014;13:135-144. [PMID: 24768040 DOI: 10.1016/j.clcc.2014.02.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
204 Peters M, Kogan NM. HU-331: a cannabinoid quinone, with uncommon cytotoxic properties and low toxicity. Expert Opin Investig Drugs 2007;16:1405-13. [PMID: 17714026 DOI: 10.1517/13543784.16.9.1405] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
205 Bezabeh B, Fleming R, Fazenbaker C, Zhong H, Coffman K, Yu XQ, Leow CC, Gibson N, Wilson S, Stover CK, Wu H, Gao C, Dimasi N. Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties. MAbs 2017;9:240-56. [PMID: 27981887 DOI: 10.1080/19420862.2016.1270492] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
206 Dong Y, Wu H, Rahman HN, Liu Y, Pasula S, Tessneer KL, Cai X, Liu X, Chang B, McManus J, Hahn S, Dong J, Brophy ML, Yu L, Song K, Silasi-Mansat R, Saunders D, Njoku C, Song H, Mehta-D'Souza P, Towner R, Lupu F, McEver RP, Xia L, Boerboom D, Srinivasan RS, Chen H. Motif mimetic of epsin perturbs tumor growth and metastasis. J Clin Invest 2015;125:4349-64. [PMID: 26571402 DOI: 10.1172/JCI80349] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
207 Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Gehrs B, Raffeld M, Kinders RJ, Parchment R, Anver MR, Shoemaker RH, Melillo G. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther 2009;8:1867-77. [PMID: 19584228 DOI: 10.1158/1535-7163.MCT-09-0274] [Cited by in Crossref: 127] [Cited by in F6Publishing: 68] [Article Influence: 9.8] [Reference Citation Analysis]
208 Ramezani S, Vousooghi N, Ramezani Kapourchali F, Joghataei MT. Perifosine enhances bevacizumab-induced apoptosis and therapeutic efficacy by targeting PI3K/AKT pathway in a glioblastoma heterotopic model. Apoptosis 2017;22:1025-34. [DOI: 10.1007/s10495-017-1382-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
209 Mandal A, Sekar S, Kanagavel M, Chandrasekaran N, Mukherjee A, Sastry T. Collagen based magnetic nanobiocomposite as MRI contrast agent and for targeted delivery in cancer therapy. Biochimica et Biophysica Acta (BBA) - General Subjects 2013;1830:4628-33. [DOI: 10.1016/j.bbagen.2013.05.018] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
210 Sari A, Adiguzel U, Canacankatan N, Yilmaz N, Dinc E, Oz O. EFFECTS OF INTRAVITREAL BEVACIZUMAB IN REPEATED DOSES: An Experimental Study. Retina 2009;29:1346-55. [DOI: 10.1097/iae.0b013e3181b26343] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
211 Tabana Y, Okoye IS, Siraki A, Elahi S, Barakat KH. Tackling Immune Targets for Breast Cancer: Beyond PD-1/PD-L1 Axis. Front Oncol 2021;11:628138. [PMID: 33747948 DOI: 10.3389/fonc.2021.628138] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
212 Soto-Ortiz L, Finley SD. A cancer treatment based on synergy between anti-angiogenic and immune cell therapies. J Theor Biol 2016;394:197-211. [PMID: 26826488 DOI: 10.1016/j.jtbi.2016.01.026] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
213 Shi C, Cao H, He W, Gao F, Liu Y, Yin L. Novel drug delivery liposomes targeted with a fully human anti-VEGF165 monoclonal antibody show superior antitumor efficacy in vivo. Biomedicine & Pharmacotherapy 2015;73:48-57. [DOI: 10.1016/j.biopha.2015.05.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
214 Campochiaro PA, Aiello LP, Rosenfeld PJ. Anti-Vascular Endothelial Growth Factor Agents in the Treatment of Retinal Disease: From Bench to Bedside. Ophthalmology. 2016;123:S78-S88. [PMID: 27664289 DOI: 10.1016/j.ophtha.2016.04.056] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 9.5] [Reference Citation Analysis]
215 Stevenson CE, Nagahashi M, Ramachandran S, Yamada A, Bear HD, Takabe K. Bevacizumab and breast cancer: what does the future hold? Future Oncol 2012;8:403-14. [PMID: 22515444 DOI: 10.2217/fon.12.22] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
216 Yonezawa H, Hirano H, Uchida H, Habu M, Hanaya R, Oyoshi T, Sadamura Y, Hanada T, Tokimura H, Moinuddin F, Arita K. Efficacy of bevacizumab therapy for unresectable malignant glioma: A retrospective analysis. Mol Clin Oncol 2017;6:105-10. [PMID: 28123740 DOI: 10.3892/mco.2016.1086] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
217 Morera Y, Bequet-Romero M, Ayala M, Pérez PP, Castro J, Sánchez J, Alba JS, Ancízar J, Cosme K, Gavilondo JV. Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non human primates. Vaccine 2012;30:368-77. [PMID: 22075086 DOI: 10.1016/j.vaccine.2011.10.082] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
218 Weitzenfeld P, Ben-Baruch A. The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer. Cancer Lett 2014;352:36-53. [PMID: 24141062 DOI: 10.1016/j.canlet.2013.10.006] [Cited by in Crossref: 89] [Cited by in F6Publishing: 92] [Article Influence: 9.9] [Reference Citation Analysis]
219 Gonzalez-Perez RR, Xu Y, Guo S, Watters A, Zhou W, Leibovich SJ. Leptin upregulates VEGF in breast cancer via canonic and non-canonical signalling pathways and NFkappaB/HIF-1alpha activation. Cell Signal. 2010;22:1350-1362. [PMID: 20466060 DOI: 10.1016/j.cellsig.2010.05.003] [Cited by in Crossref: 101] [Cited by in F6Publishing: 102] [Article Influence: 8.4] [Reference Citation Analysis]
220 Baker JHE, Kyle AH, Reinsberg SA, Moosvi F, Patrick HM, Cran J, Saatchi K, Häfeli U, Minchinton AI. Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment. Clin Exp Metastasis 2018;35:691-705. [PMID: 30196384 DOI: 10.1007/s10585-018-9929-3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
221 Soleimanizadeh M, Jalali Javaran M, Bagheri A, Behdani M. Apoplastic Production of Recombinant AntiVEGF Protein Using Plant-Virus Transient Expression Vector. Mol Biotechnol 2022. [PMID: 35332419 DOI: 10.1007/s12033-022-00483-3] [Reference Citation Analysis]
222 Sleeckx N, Van Brantegem L, Van den Eynden G, Fransen E, Casteleyn C, Van Cruchten S, Veldhuis Kroeze E, Van Ginneken C. Lymphangiogenesis in Canine Mammary Tumours: A Morphometric and Prognostic Study. Journal of Comparative Pathology 2014;150:184-93. [DOI: 10.1016/j.jcpa.2013.09.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
223 Baxevanis CN. Antibody-based cancer therapy. Expert Opin Drug Discov 2008;3:441-52. [PMID: 23489099 DOI: 10.1517/17460441.3.4.441] [Reference Citation Analysis]
224 Bhatia SK. Translation of Pro-Angiogenic and Anti-Angiogenic Therapies into Clinical Use. In: Reinhart-king CA, editor. Mechanical and Chemical Signaling in Angiogenesis. Berlin: Springer Berlin Heidelberg; 2013. pp. 261-78. [DOI: 10.1007/978-3-642-30856-7_13] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
225 Ruppen I, Beydon ME, Solís C, Sacristán D, Vandenheede I, Ortiz A, Sandra K, Adhikary L. Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization. Biologicals 2021;73:41-56. [PMID: 34593306 DOI: 10.1016/j.biologicals.2021.09.001] [Reference Citation Analysis]
226 Bressler SB. Introduction: Understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. Ophthalmology 2009;116:S1-7. [PMID: 19800534 DOI: 10.1016/j.ophtha.2009.06.045] [Cited by in Crossref: 104] [Cited by in F6Publishing: 109] [Article Influence: 8.0] [Reference Citation Analysis]
227 Chévez-barrios P. Are we getting closer to prevention and treatment of corneal neovascularization? Clin Exp Ophthalmol 2007;35:689-90. [DOI: 10.1111/j.1442-9071.2007.01616.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
228 Beer PM, Wong SJ, Hammad AM, Falk NS, O’malley MR, Khan S. VITREOUS LEVELS OF UNBOUND BEVACIZUMAB AND UNBOUND VASCULAR ENDOTHELIAL GROWTH FACTOR IN TWO PATIENTS. Retina 2006;26:871-6. [DOI: 10.1097/01.iae.0000233327.68433.02] [Cited by in Crossref: 77] [Cited by in F6Publishing: 73] [Article Influence: 4.8] [Reference Citation Analysis]
229 Hu WH, Chan GK, Duan R, Wang HY, Kong XP, Dong TT, Tsim KW. Synergy of Ginkgetin and Resveratrol in Suppressing VEGF-Induced Angiogenesis: A Therapy in Treating Colorectal Cancer. Cancers (Basel) 2019;11:E1828. [PMID: 31757048 DOI: 10.3390/cancers11121828] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
230 Hosny MH, Zayed MA, Shalaby AM, Eissa IM. Effect of intracameral bevacizumab injection on corneal endothelial cells: an in vivo evaluation. J Ocul Pharmacol Ther 2009;25:513-7. [PMID: 19929596 DOI: 10.1089/jop.2009.0056] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
231 Sadeghi A, Behdani M, Muyldermans S, Habibi-Anbouhi M, Kazemi-Lomedasht F. Development of a mono-specific anti-VEGF bivalent nanobody with extended plasma half-life for treatment of pathologic neovascularization. Drug Test Anal 2020;12:92-100. [PMID: 31476257 DOI: 10.1002/dta.2693] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
232 Van Buren Ii G, Camp ER, Yang AD, Gray MJ, Fan F, Somcio R, Ellis LM. The role of nitric oxide in mediating tumour blood flow. Expert Opinion on Therapeutic Targets 2006;10:689-701. [DOI: 10.1517/14728222.10.5.689] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
233 Sunil AA, Skaria T. Novel regulators of airway epithelial barrier function during inflammation: potential targets for drug repurposing. Expert Opin Ther Targets 2022. [PMID: 35085478 DOI: 10.1080/14728222.2022.2035720] [Reference Citation Analysis]
234 Rüegg C. Leukocytes, inflammation, and angiogenesis in cancer: fatal attractions. J Leukoc Biol. 2006;80:682-684. [PMID: 16849612 DOI: 10.1189/jlb.0606394] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 3.1] [Reference Citation Analysis]
235 Lahooti B, Poudel S, Mikelis CM, Mattheolabakis G. MiRNAs as Anti-Angiogenic Adjuvant Therapy in Cancer: Synopsis and Potential. Front Oncol 2021;11:705634. [PMID: 34956857 DOI: 10.3389/fonc.2021.705634] [Reference Citation Analysis]
236 Naeem A, Tun AM, Guevara E. Molecular Genetics and the Role of Molecularly Targeted Agents in Metastatic Colorectal Carcinoma. J Gastrointest Cancer 2020;51:387-400. [PMID: 31273629 DOI: 10.1007/s12029-019-00272-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
237 Dong Z, Zeitlin BD, Song W, Sun Q, Karl E, Spencer DM, Jain HV, Jackson T, Núñez G, Nör JE. Level of endothelial cell apoptosis required for a significant decrease in microvessel density. Exp Cell Res 2007;313:3645-57. [PMID: 17720154 DOI: 10.1016/j.yexcr.2007.07.023] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
238 Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One. 2008;3:e3077. [PMID: 18728788 DOI: 10.1371/journal.pone.0003077] [Cited by in Crossref: 304] [Cited by in F6Publishing: 289] [Article Influence: 21.7] [Reference Citation Analysis]
239 Verdaguer H, Tabernero J, Macarulla T. Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy. Ther Adv Med Oncol. 2016;8:230-242. [PMID: 27239240 DOI: 10.1177/1758834016635888] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
240 Hutchinson LG, Gaffney EA, Maini PK, Wagg J, Phipps A, Byrne HM. Vascular phenotype identification and anti-angiogenic treatment recommendation: A pseudo-multiscale mathematical model of angiogenesis. J Theor Biol 2016;398:162-80. [PMID: 26987523 DOI: 10.1016/j.jtbi.2016.03.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
241 Lai YD, Wu YY, Tsai YJ, Tsai YS, Lin YY, Lai SL, Huang CY, Lok YY, Hu CY, Lai JS. Generation of Potent Anti-Vascular Endothelial Growth Factor Neutralizing Antibodies from Mouse Phage Display Library for Cancer Therapy. Int J Mol Sci 2016;17:214. [PMID: 26861297 DOI: 10.3390/ijms17020214] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
242 Weis SM. Evaluation of VEGF-induced vascular permeability in mice. Methods Mol Biol 2011;763:403-15. [PMID: 21874467 DOI: 10.1007/978-1-61779-191-8_27] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
243 Aguirre AR, Abensur H. Protective measures against ultrafiltration failure in peritoneal dialysis patients. Clinics (Sao Paulo) 2011;66:2151-7. [PMID: 22189743 DOI: 10.1590/s1807-59322011001200023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
244 Jorge S, Goff BA, Gray HJ, Enquobahrie DA, Doll KM. Characterization of the Early Years of Bevacizumab Use for First-Line Treatment of Ovarian Cancer in the United States. JCO Oncol Pract 2021;:OP2000918. [PMID: 33844592 DOI: 10.1200/OP.20.00918] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
245 Yanagisawa K, Konno M, Liu H, Irie S, Mizushima T, Mori M, Doki Y, Eguchi H, Matsusaki M, Ishii H. A Four-Dimensional Organoid System to Visualize Cancer Cell Vascular Invasion. Biology (Basel) 2020;9:E361. [PMID: 33120912 DOI: 10.3390/biology9110361] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
246 Ayyıldız O, Durukan AH, Ozgurtas T, Gunal A. A Comparison of Intravitreal Bevacizumab and Steroid Activity in an Experimental Uveitis Model. Current Eye Research 2014;40:1261-8. [DOI: 10.3109/02713683.2014.995310] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
247 Sato M, Yao VJ, Arap W, Pasqualini R. GRP78 signaling hub a receptor for targeted tumor therapy. Adv Genet. 2010;69:97-114. [PMID: 20807604 DOI: 10.1016/s0065-2660(10)69006-2] [Cited by in Crossref: 64] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
248 Mallidi S, Spring BQ, Hasan T. Optical Imaging, Photodynamic Therapy and Optically Triggered Combination Treatments. Cancer J 2015;21:194-205. [PMID: 26049699 DOI: 10.1097/PPO.0000000000000117] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
249 Matsumoto K, Obara N, Ema M, Horie M, Naka A, Takahashi S, Imagawa S. Antitumor effects of 2-oxoglutarate through inhibition of angiogenesis in a murine tumor model. Cancer Sci 2009;100:1639-47. [PMID: 19575748 DOI: 10.1111/j.1349-7006.2009.01249.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
250 Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60:1615-1626. [PMID: 18840489 DOI: 10.1016/j.addr.2008.08.005] [Cited by in Crossref: 1099] [Cited by in F6Publishing: 989] [Article Influence: 78.5] [Reference Citation Analysis]
251 Zhou YT, Cai WW, Li Y, Jiang X, Feng L, Zhu QY, Liu YL, Chen YX, Li SS, Du B, Lang F, Wu PX, Qiu LY. Correlations between quantitative parameters of contrast-enhanced ultrasound and vasculogenic mimicry in murine tumor model: a novel noninvasive technique for assessment? Biol Proced Online 2019;21:11. [PMID: 31205452 DOI: 10.1186/s12575-019-0101-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
252 Castermans K, Tabruyn SP, Zeng R, van Beijnum JR, Eppolito C, Leonard WJ, Shrikant PA, Griffioen AW. Angiostatic activity of the antitumor cytokine interleukin-21. Blood 2008;112:4940-7. [PMID: 18515660 DOI: 10.1182/blood-2007-09-113878] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
253 Quiroz-mercado H, Ustariz-gonzález O, Martinez-castellanos MA, Covarrubias P, Dominguez F, Sanchez-huerta V. Our Experience After 1765 Intravitreal Injections of Bevacizumab: The Importance of Being Part of a Developing Story. Seminars in Ophthalmology 2009;22:109-25. [DOI: 10.1080/08820530701420082] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
254 Dervisis N, Klahn S. Therapeutic Innovations: Tyrosine Kinase Inhibitors in Cancer. Vet Sci 2016;3:E4. [PMID: 29056714 DOI: 10.3390/vetsci3010004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
255 Liu YX, Xu BW, Niu XD, Chen YJ, Fu XQ, Wang XQ, Yin CL, Chou JY, Li JK, Wu JY, Bai JX, Wu Y, Li SM, Yu ZL. Inhibition of Src/STAT3 signaling-mediated angiogenesis is involved in the anti-melanoma effects of dioscin. Pharmacol Res 2021;175:105983. [PMID: 34822972 DOI: 10.1016/j.phrs.2021.105983] [Reference Citation Analysis]
256 Keefe D, Bowen J, Gibson R, Tan T, Okera M, Stringer A. Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. Oncologist 2011;16:432-44. [PMID: 21441297 DOI: 10.1634/theoncologist.2010-0271] [Cited by in Crossref: 62] [Cited by in F6Publishing: 43] [Article Influence: 5.6] [Reference Citation Analysis]
257 Reiners KS, Gossmann A, von Strandmann EP, Böll B, Engert A, Borchmann P. Effects of the Anti-VEGF Monoclonal Antibody Bevacizumab in a Preclinical Model and in Patients With Refractory and Multiple Relapsed Hodgkin Lymphoma. Journal of Immunotherapy 2009;32:508-12. [DOI: 10.1097/cji.0b013e3181a25daf] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
258 Allegra A, Penna G, Alonci A, Russo S, Greve B, Innao V, Minardi V, Musolino C. Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma. Eur J Haematol 2013;90:441-68. [DOI: 10.1111/ejh.12107] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
259 Reinacher-Schick A, Pohl M, Schmiegel W. Drug insight: antiangiogenic therapies for gastrointestinal cancers--focus on monoclonal antibodies. Nat Clin Pract Gastroenterol Hepatol 2008;5:250-67. [PMID: 18382435 DOI: 10.1038/ncpgasthep1097] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
260 Jászai J, Schmidt MHH. Trends and Challenges in Tumor Anti-Angiogenic Therapies. Cells 2019;8:E1102. [PMID: 31540455 DOI: 10.3390/cells8091102] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 18.7] [Reference Citation Analysis]
261 Loupakis F, Falcone A, Masi G, Fioravanti A, Kerbel RS, Del Tacca M, Bocci G. Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. J Clin Oncol. 2007;25:1816-1818. [PMID: 17470880 DOI: 10.1200/jco.2006.10.3051] [Cited by in Crossref: 49] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
262 Alirahimi E, Ashkiyan A, Kazemi-Lomedasht F, Azadmanesh K, Hosseininejad-Chafi M, Habibi-Anbouhi M, Moazami R, Behdani M. Intrabody targeting vascular endothelial growth factor receptor-2 mediates downregulation of surface localization. Cancer Gene Ther 2017;24:33-7. [PMID: 27982020 DOI: 10.1038/cgt.2016.76] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
263 Foxton RH, Finkelstein A, Vijay S, Dahlmann-Noor A, Khaw PT, Morgan JE, Shima DT, Ng YS. VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma. Am J Pathol 2013;182:1379-90. [PMID: 23416159 DOI: 10.1016/j.ajpath.2012.12.032] [Cited by in Crossref: 101] [Cited by in F6Publishing: 103] [Article Influence: 11.2] [Reference Citation Analysis]
264 Cheng N, Bai X, Shu Y, Ahmad O, Shen P. Targeting tumor-associated macrophages as an antitumor strategy. Biochem Pharmacol 2021;183:114354. [PMID: 33279498 DOI: 10.1016/j.bcp.2020.114354] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
265 Mason RP, Zhao D, Liu L, Trawick ML, Pinney KG. A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment. Integr Biol (Camb) 2011;3:375-87. [PMID: 21321746 DOI: 10.1039/c0ib00135j] [Cited by in Crossref: 71] [Cited by in F6Publishing: 71] [Article Influence: 6.5] [Reference Citation Analysis]
266 Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Ikeuchi H. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients. Dis Colon Rectum. 2011;54:1026-1035. [PMID: 21730794 DOI: 10.1097/dcr.0b013e31821c44af] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
267 Varani M, Galli F, Capriotti G, Mattei M, Cicconi R, Campagna G, Panzuto F, Signore A. Theranostic Designed Near-Infrared Fluorescent Poly (Lactic-co-Glycolic Acid) Nanoparticles and Preliminary Studies with Functionalized VEGF-Nanoparticles. J Clin Med 2020;9:E1750. [PMID: 32516917 DOI: 10.3390/jcm9061750] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
268 Watanabe M, Boyer JL, Hackett NR, Qiu J, Crystal RG. Gene Delivery of the Murine Equivalent of Bevacizumab (Avastin), an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody, to Suppress Growth of Human Tumors in Immunodeficient Mice. Human Gene Therapy 2008;19:300-10. [DOI: 10.1089/hum.2007.109] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
269 Fleuren ED, Versleijen-jonkers YM, Roeffen MH, Franssen GM, Flucke UE, Houghton PJ, Oyen WJ, Boerman OC, van der Graaf WT. Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models: Temsirolimus with Cisplatin or Bevacizumab in Osteosarcoma. Int J Cancer 2014;135:2770-82. [DOI: 10.1002/ijc.28933] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
270 Jay JW, Bray B, Qi Y, Igbinigie E, Wu H, Li J, Ren G. IgG Antibody 3D Structures and Dynamics. Antibodies (Basel) 2018;7:E18. [PMID: 31544870 DOI: 10.3390/antib7020018] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
271 Yudistiro R, Hanaoka H, Katsumata N, Yamaguchi A, Tsushima Y. Bevacizumab Radioimmunotherapy (RIT) with Accelerated Blood Clearance Using the Avidin Chase. Mol Pharm 2018;15:2165-73. [PMID: 29733658 DOI: 10.1021/acs.molpharmaceut.8b00027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
272 Cao D, Guo CH, Liu JW, Yang X, Li Q. Bleeding after bevacizumab treatment in patients with metastatic colorectal cancer. Tumori 2015;101:46-51. [PMID: 25702674 DOI: 10.5301/tj.5000211] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
273 Karroum A, Mirshahi P, Faussat AM, Therwath A, Mirshahi M, Hatmi M. Tubular network formation by adriamycin-resistant MCF-7 breast cancer cells is closely linked to MMP-9 and VEGFR-2/VEGFR-3 over-expressions. Eur J Pharmacol. 2012;685:1-7. [PMID: 22542663 DOI: 10.1016/j.ejphar.2012.04.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
274 Tkaczuk A, Trivedi S, Mody MD, Steuer CE, Shin DM, Klein AM, Saba NF. Parenteral Bevacizumab for the Treatment of Severe Respiratory Papillomatosis in an Adult Population. Laryngoscope 2021;131:E921-8. [PMID: 33107615 DOI: 10.1002/lary.29133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
275 Grau SJ, Trillsch F, Herms J, Thon N, Nelson PJ, Tonn JC, Goldbrunner R. Expression of VEGFR3 in glioma endothelium correlates with tumor grade. J Neurooncol 2007;82:141-50. [PMID: 17115285 DOI: 10.1007/s11060-006-9272-4] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 2.7] [Reference Citation Analysis]
276 Seet RCS, Rabinstein AA. Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment. QJM 2011;105:69-75. [DOI: 10.1093/qjmed/hcr139] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 5.2] [Reference Citation Analysis]
277 Chen B, Lin SJ, Li WT, Chang HW, Pang VF, Chu PY, Lee CC, Nakayama H, Wu CH, Jeng CR. Expression of HIF-1α and VEGF in feline mammary gland carcinomas: association with pathological characteristics and clinical outcomes. BMC Vet Res 2020;16:125. [PMID: 32375802 DOI: 10.1186/s12917-020-02338-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
278 Black DE, Veldtman GR, Bryant T, Miller J, Haw M. Catastrophic haemoptysis in the Fontan circulation--a novel surgical approach to denude the culprit bleeding vessels. Cardiol Young 2011;21:462-4. [PMID: 21349234 DOI: 10.1017/S1047951111000163] [Reference Citation Analysis]
279 Mohammadpour M, Jabbarvand M, Hashemi H, Delrish E. Prophylactic effect of topical silica nanoparticles as a novel antineovascularization agent for inhibiting corneal neovascularization following chemical burn. Adv Biomed Res 2015;4:124. [PMID: 26261826 DOI: 10.4103/2277-9175.158039] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
280 Matsumoto K, Nakamura T. Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int J Cancer 2006;119:477-83. [PMID: 16453287 DOI: 10.1002/ijc.21808] [Cited by in Crossref: 159] [Cited by in F6Publishing: 138] [Article Influence: 9.9] [Reference Citation Analysis]
281 Liu Y, Suzuki M, Masunaga S, Chen YW, Kashino G, Tanaka H, Sakurai Y, Kirihata M, Ono K. Effect of bevacizumab treatment on p-boronophenylalanine distribution in murine tumor. J Radiat Res 2013;54:260-7. [PMID: 23135099 DOI: 10.1093/jrr/rrs102] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
282 Liu T, Shi C, Duan L, Zhang Z, Luo L, Goel S, Cai W, Chen T. A highly hemocompatible erythrocyte membrane-coated ultrasmall selenium nanosystem for simultaneous cancer radiosensitization and precise antiangiogenesis. J Mater Chem B 2018;6:4756-64. [PMID: 30450208 DOI: 10.1039/C8TB01398E] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 6.3] [Reference Citation Analysis]
283 Jiang Y, Liang X, Li X, Tao Y, Wang K. Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy. Acta Ophthalmol 2009;87:736-40. [PMID: 18803622 DOI: 10.1111/j.1755-3768.2008.01353.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
284 Hu HQ, Sun YN, Luo SP, Zhou Q, Tao FL, Chen Z, Xu Y, Zhou Q. Generation of a mouse monoclonal antibody recognizing both the native and denatured forms of human VEGF. Hybridoma (Larchmt) 2009;28:51-7. [PMID: 19207011 DOI: 10.1089/hyb.2008.0059] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
285 Patel AR, Chougule MB, Lim E, Francis KP, Safe S, Singh M. Theranostic tumor homing nanocarriers for the treatment of lung cancer. Nanomedicine 2014;10:1053-63. [PMID: 24355163 DOI: 10.1016/j.nano.2013.12.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
286 Motarjemizadeh Q, Aidenloo NS, Sepehri S. A comparative study of different concentrations of topical bevacizumab on the recurrence rate of excised primary pterygium: a short-term follow-up study. Int Ophthalmol 2016;36:63-71. [PMID: 25943172 DOI: 10.1007/s10792-015-0076-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
287 Kazemi-lomedasht F, Behdani M, Habibi-anbouhi M, Shahbazzadeh D. Production and Characterization of Novel Camel Single Domain Antibody Targeting Mouse Vascular Endothelial Growth Factor. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy 2016;35:167-71. [DOI: 10.1089/mab.2016.0001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
288 Savai R, Langheinrich AC, Schermuly RT, Pullamsetti SS, Dumitrascu R, Traupe H, Rau WS, Seeger W, Grimminger F, Banat GA. Evaluation of angiogenesis using micro-computed tomography in a xenograft mouse model of lung cancer. Neoplasia 2009;11:48-56. [PMID: 19107231 DOI: 10.1593/neo.81036] [Cited by in Crossref: 76] [Cited by in F6Publishing: 68] [Article Influence: 5.8] [Reference Citation Analysis]
289 Saif MW. Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike? Cancer Manag Res. 2013;5:103-115. [PMID: 23807861 DOI: 10.2147/cmar.s45193] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
290 Hopp RN, Pucci J, Santos-silva AR, Jorge J. Osteonecrosis After Administration of Intravitreous Bevacizumab. Journal of Oral and Maxillofacial Surgery 2012;70:632-5. [DOI: 10.1016/j.joms.2011.02.104] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
291 Schwartzberg LS, Badarinath S, Keaton MR, Childs BH. Phase II multicenter study of docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer. Clin Breast Cancer 2014;14:161-8. [PMID: 24566467 DOI: 10.1016/j.clbc.2013.12.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
292 Kumar B, Chile SA, Ray KB, Vidyadhar Reddy GEC, Addepalli MK, Manoj Kumar AS, Ramana V, Rajagopal V. VEGF-C differentially regulates VEGF-A expression in ocular and cancer cells; promotes angiogenesis via RhoA mediated pathway. Angiogenesis 2011;14:371-80. [DOI: 10.1007/s10456-011-9221-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
293 Chen K, Li Z, Wang H, Cai W, Chen X. Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots. Eur J Nucl Med Mol Imaging 2008;35:2235-44. [DOI: 10.1007/s00259-008-0860-8] [Cited by in Crossref: 145] [Cited by in F6Publishing: 125] [Article Influence: 10.4] [Reference Citation Analysis]
294 Seebacher NA, Stacy AE, Porter GM, Merlot AM. Clinical development of targeted and immune based anti-cancer therapies. J Exp Clin Cancer Res 2019;38:156. [PMID: 30975211 DOI: 10.1186/s13046-019-1094-2] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 19.3] [Reference Citation Analysis]
295 Rahmathulla G, Hovey EJ, Hashemi-Sadraei N, Ahluwalia MS. Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges. Onco Targets Ther 2013;6:371-89. [PMID: 23620671 DOI: 10.2147/OTT.S38628] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
296 Kameswaran M, Pandey U, Gamre N, Vimalnath KV, Sarma HD, Dash A. Evaluation of (177)Lu-CHX-A''-DTPA-Bevacizumab as a radioimmunotherapy agent targeting VEGF expressing cancers. Appl Radiat Isot 2016;114:196-201. [PMID: 27258216 DOI: 10.1016/j.apradiso.2016.05.025] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
297 Adamcic U, Skowronski K, Peters C, Morrison J, Coomber BL. The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops. Neoplasia 2012;14:612-23. [PMID: 22904678 DOI: 10.1593/neo.11948] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
298 Azam F, Mehta S, Harris AL. Mechanisms of resistance to antiangiogenesis therapy. Eur J Cancer 2010;46:1323-32. [PMID: 20236818 DOI: 10.1016/j.ejca.2010.02.020] [Cited by in Crossref: 116] [Cited by in F6Publishing: 109] [Article Influence: 9.7] [Reference Citation Analysis]
299 Zhang Q, Lao X, Huang J, Zhu Z, Pang L, Tang Y, Song Q, Huang J, Deng J, Deng N, Yang Q, Sengupta AM, Xiong L. Soluble production and function of vascular endothelial growth factor/basic fibroblast growth factor complex peptide. Biotechnol Prog 2015;31:194-203. [PMID: 25271020 DOI: 10.1002/btpr.1997] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
300 Cámara-Quílez M, Barreiro-Alonso A, Vizoso-Vázquez Á, Rodríguez-Belmonte E, Quindós-Varela M, Lamas-Maceiras M, Cerdán ME. The HMGB1-2 Ovarian Cancer Interactome. The Role of HMGB Proteins and Their Interacting Partners MIEN1 and NOP53 in Ovary Cancer and Drug-Response. Cancers (Basel) 2020;12:E2435. [PMID: 32867128 DOI: 10.3390/cancers12092435] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
301 Jurado García JM, Sánchez A, Pajares B, Pérez E, Alonso L, Alba E. Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer. Clin Transl Oncol 2008;10:583-6. [DOI: 10.1007/s12094-008-0254-7] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 3.5] [Reference Citation Analysis]
302 Ortiz LD, Syro LV, Scheithauer BW, Ersen A, Uribe H, Fadul CE, Rotondo F, Horvath E, Kovacs K. Anti-VEGF therapy in pituitary carcinoma. Pituitary. 2012;15:445-449. [PMID: 21918831 DOI: 10.1007/s11102-011-0346-8] [Cited by in Crossref: 77] [Cited by in F6Publishing: 67] [Article Influence: 8.6] [Reference Citation Analysis]
303 Butowski NA, Chang SM. General and neurological complications of targeted therapy. Handb Clin Neurol 2012;105:937-45. [PMID: 22230543 DOI: 10.1016/B978-0-444-53502-3.00033-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
304 Michailidou M, Giannouli V, Kotsikoris V, Papadodima O, Kontogianni G, Kostakis IK, Lougiakis N, Chatziioannou A, Kolisis FN, Marakos P, Pouli N, Loutrari H. Novel pyrazolopyridine derivatives as potential angiogenesis inhibitors: Synthesis, biological evaluation and transcriptome-based mechanistic analysis. Eur J Med Chem 2016;121:143-57. [PMID: 27240270 DOI: 10.1016/j.ejmech.2016.05.035] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
305 Rao SS, El Abiad JM, Puvanesarajah V, Levin AS, Jones LC, Morris CD. Osteonecrosis in pediatric cancer survivors: Epidemiology, risk factors, and treatment. Surg Oncol 2019;28:214-21. [PMID: 30851903 DOI: 10.1016/j.suronc.2019.02.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
306 Nemati S, Keihanian F, Saeidinia A, Bakhshaei M. Effect Of Bevacizumab On Growth Of Human Nasal Polyposis In Vitro; An Off-Label Use Of Anti-Angiogenic Agent For Nasal Polyposis Treatment. Drug Des Devel Ther 2019;13:3383-9. [PMID: 31576112 DOI: 10.2147/DDDT.S219724] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
307 Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370:699-708. [PMID: 24552317 DOI: 10.1056/nejmoa1308573] [Cited by in Crossref: 1556] [Cited by in F6Publishing: 894] [Article Influence: 194.5] [Reference Citation Analysis]
308 Shen J, Vil MD, Prewett M, Damoci C, Zhang H, Li H, Jimenez X, Deevi DS, Iacolina M, Kayas A, Bassi R, Persaud K, Rohoza-Asandi A, Balderes P, Loizos N, Ludwig DL, Tonra J, Witte L, Zhu Z. Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody. Neoplasia 2009;11:594-604. [PMID: 19484148 DOI: 10.1593/neo.09278] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 3.5] [Reference Citation Analysis]
309 Deshayes S, Maurizot V, Clochard M, Baudin C, Berthelot T, Esnouf S, Lairez D, Moenner M, Déléris G. “Click” Conjugation of Peptide on the Surface of Polymeric Nanoparticles for Targeting Tumor Angiogenesis. Pharm Res 2011;28:1631-42. [DOI: 10.1007/s11095-011-0398-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
310 Liu S, Li H, Xia L, Xu P, Ding Y, Huo D, Hu Y. Anti-RhoJ antibody functionalized Au@I nanoparticles as CT-guided tumor vessel-targeting radiosensitizers in patient-derived tumor xenograft model. Biomaterials 2017;141:1-12. [PMID: 28666098 DOI: 10.1016/j.biomaterials.2017.06.036] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
311 Chung JY, Ul Ain Q, Lee HL, Kim S, Kim Y. Enhanced Systemic Anti-Angiogenic siVEGF Delivery Using PEGylated Oligo- d -arginine. Mol Pharmaceutics 2017;14:3059-68. [DOI: 10.1021/acs.molpharmaceut.7b00282] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
312 Aurora AB, Biyashev D, Mirochnik Y, Zaichuk TA, Sánchez-Martinez C, Renault MA, Losordo D, Volpert OV. NF-kappaB balances vascular regression and angiogenesis via chromatin remodeling and NFAT displacement. Blood. 2010;116:475-484. [PMID: 20203265 DOI: 10.1182/blood-2009-07-232132] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 4.5] [Reference Citation Analysis]
313 Krasner CN, Campos SM, Young CL, Chadda KR, Lee H, Birrer MJ, Horowitz NS, Konstantinopoulos PA, D'Ascanio AM, Matulonis UA, Penson RT. Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer. Gynecol Oncol 2021;162:661-6. [PMID: 34243976 DOI: 10.1016/j.ygyno.2021.07.002] [Reference Citation Analysis]
314 Wang M, Zeng Q, Li Y, Imani S, Xie D, Li Y, Han Y, Fan J. Bevacizumab combined with apatinib enhances antitumor and anti-angiogenesis effects in a lung cancer model in vitro and in vivo. J Drug Target 2020;28:961-9. [PMID: 32374627 DOI: 10.1080/1061186X.2020.1764963] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
315 Singh SK, Kumar D, Malani H, Rathore AS. LC-MS based case-by-case analysis of the impact of acidic and basic charge variants of bevacizumab on stability and biological activity. Sci Rep 2021;11:2487. [PMID: 33514790 DOI: 10.1038/s41598-020-79541-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
316 Peters KB, Coyle TE, Vredenburgh JJ, Desjardins A, Friedman HS, Reardon DA. Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy. J Neurooncol 2011;101:155-9. [PMID: 20524043 DOI: 10.1007/s11060-010-0239-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
317 Zhu R, Wang Z, Liang P, He X, Zhuang X, Huang R, Wang M, Wang Q, Qian Y, Wang S. Efficient VEGF targeting delivery of DOX using Bevacizumab conjugated SiO2@LDH for anti-neuroblastoma therapy. Acta Biomater 2017;63:163-80. [PMID: 28923539 DOI: 10.1016/j.actbio.2017.09.009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
318 Dursun A, Arici MK, Dursun F, Ozec AV, Toker MI, Erdogan H, Topalkara A. Comparison of the effects of bevacizumab and ranibizumab injection on corneal angiogenesis in an alkali burn induced model. Int J Ophthalmol 2012;5:448-51. [PMID: 22937503 DOI: 10.3980/j.issn.2222-3959.2012.04.08] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
319 Li X, Claesson-Welsh L, Shibuya M. VEGF receptor signal transduction. Methods Enzymol. 2008;443:261-284. [PMID: 18772020 DOI: 10.1016/s0076-6879(08)02013-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
320 Ruiz Ciancio D, Vargas MR, Thiel WH, Bruno MA, Giangrande PH, Mestre MB. Aptamers as Diagnostic Tools in Cancer. Pharmaceuticals (Basel) 2018;11:E86. [PMID: 30208607 DOI: 10.3390/ph11030086] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
321 Nosaka C, Adachi H, Sawa R, Nakae K, Atsumi S, Kinoshita N, Kubota Y, Igarashi M, Sei Y, Yamaguchi K, Shibuya M, Nishimura Y, Akamatsu Y. Vegfrecine, an inhibitor of VEGF receptor tyrosine kinases isolated from the culture broth of Streptomyces sp. J Nat Prod 2013;76:715-9. [PMID: 23414235 DOI: 10.1021/np300535c] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
322 Lee YJ, Karl DL, Maduekwe UN, Rothrock C, Ryeom S, D'Amore PA, Yoon SS. Differential effects of VEGFR-1 and VEGFR-2 inhibition on tumor metastases based on host organ environment. Cancer Res 2010;70:8357-67. [PMID: 20978198 DOI: 10.1158/0008-5472.CAN-10-1138] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
323 Norouzi M, Nazari B, Miller DW. Injectable hydrogel-based drug delivery systems for local cancer therapy. Drug Discov Today 2016;21:1835-49. [PMID: 27423369 DOI: 10.1016/j.drudis.2016.07.006] [Cited by in Crossref: 174] [Cited by in F6Publishing: 157] [Article Influence: 29.0] [Reference Citation Analysis]
324 Zayit-soudry S, Zemel E, Barak A, Perlman I, Loewenstein A. SAFETY OF INTRAVITREAL BEVACIZUMAB IN THE DEVELOPING RABBIT RETINA: . Retina 2011;31:1885-95. [DOI: 10.1097/iae.0b013e31821a88e2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
325 Basbug M, Bulbuller N, Camci C, Ayten R, Aygen E, Ozercan IH, Arikanoglu Z, Akbulut S. The effect of antivascular endothelial growth factor on the development of adhesion formation in laparotomized rats: experimental study. Gastroenterol Res Pract 2011;2011:578691. [PMID: 21760775 DOI: 10.1155/2011/578691] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
326 Bellati F, Napoletano C, Ruscito I, Pastore M, Pernice M, Antonilli M, Nuti M, Benedetti Panici P. Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review. Invest New Drugs. 2010;28:887-894. [PMID: 19936983 DOI: 10.1007/s10637-009-9351-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
327 Martin JY, Urban RR, Liao JB, Goff BA. Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers. J Gynecol Oncol 2016;27:e47. [PMID: 27329195 DOI: 10.3802/jgo.2016.27.e47] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
328 Lin H, Yang Y, Hou C, Zheng J, Lv G, Mao R, Xu P, Chen S, Zhou Y, Wang P, Zhou D. Identification of COL6A1 as the Key Gene Associated with Antivascular Endothelial Growth Factor Therapy in Glioblastoma Multiforme. Genet Test Mol Biomarkers 2021;25:334-45. [PMID: 33970702 DOI: 10.1089/gtmb.2020.0279] [Reference Citation Analysis]
329 Nicosia RF, Ligresti G, Aplin AC. Preparation and Analysis of Aortic Ring Cultures for the Study of Angiogenesis Ex Vivo. In: Zudaire E, Cuttitta F, editors. The Textbook of Angiogenesis and Lymphangiogenesis: Methods and Applications. Dordrecht: Springer Netherlands; 2012. pp. 127-48. [DOI: 10.1007/978-94-007-4581-0_7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
330 Garofalo A, Goossens L, Lemoine A, Ravez S, Six P, Howsam M, Farce A, Depreux P. [4-(6,7-Disubstituted quinazolin-4-ylamino)phenyl] carbamic acid esters: a novel series of dual EGFR/VEGFR-2 tyrosine kinase inhibitors. Med Chem Commun 2011;2:65-72. [DOI: 10.1039/c0md00183j] [Cited by in Crossref: 33] [Article Influence: 3.0] [Reference Citation Analysis]
331 Moshal KS, Ferri-lagneau KF, Leung T. Zebrafish Model: Worth Considering in Defining Tumor Angiogenesis. Trends in Cardiovascular Medicine 2010;20:114-9. [DOI: 10.1016/j.tcm.2010.10.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
332 Falavarjani KG, Aghamirsalim M, Modarres M, Hadavandkhani A, Hashemi M, Parvaresh MM, Naseripour M, Samiy N. Endophthalmitis after resident-performed intravitreal bevacizumab injection. Canadian Journal of Ophthalmology 2015;50:33-6. [DOI: 10.1016/j.jcjo.2014.09.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
333 Butowski N. Anti-angiogenic therapy in glioma. Clin Transl Oncol 2011;13:294-300. [PMID: 21596656 DOI: 10.1007/s12094-011-0657-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
334 Walker EJ, Su H, Shen F, Degos V, Amend G, Jun K, Young WL. Bevacizumab attenuates VEGF-induced angiogenesis and vascular malformations in the adult mouse brain. Stroke 2012;43:1925-30. [PMID: 22569934 DOI: 10.1161/STROKEAHA.111.647982] [Cited by in Crossref: 67] [Cited by in F6Publishing: 39] [Article Influence: 6.7] [Reference Citation Analysis]
335 Kaumaya PT. A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy. Hum Vaccin Immunother 2015;11:1368-86. [PMID: 25874884 DOI: 10.1080/21645515.2015.1026495] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
336 Domingues I, Rino J, Demmers JA, de Lanerolle P, Santos SC. VEGFR2 translocates to the nucleus to regulate its own transcription. PLoS One 2011;6:e25668. [PMID: 21980525 DOI: 10.1371/journal.pone.0025668] [Cited by in Crossref: 62] [Cited by in F6Publishing: 64] [Article Influence: 5.6] [Reference Citation Analysis]
337 Jarrett AM, Bloom MJ, Godfrey W, Syed AK, Ekrut DA, Ehrlich LI, Yankeelov TE, Sorace AG. Mathematical modelling of trastuzumab-induced immune response in an in vivo murine model of HER2+ breast cancer. Math Med Biol 2019;36:381-410. [PMID: 30239754 DOI: 10.1093/imammb/dqy014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
338 Smail SW, Saeed M, Twana Alkasalias, Khudhur ZO, Younus DA, Rajab MF, Abdulahad WH, Hussain HI, Niaz K, Safdar M. Inflammation, immunity and potential target therapy of SARS-COV-2: A total scale analysis review. Food Chem Toxicol 2021;150:112087. [PMID: 33640537 DOI: 10.1016/j.fct.2021.112087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
339 Rosenfeld PJ. Optical Coherence Tomography and the Development of Antiangiogenic Therapies in Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci 2016;57:OCT14-26. [PMID: 27409464 DOI: 10.1167/iovs.16-19969] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 8.4] [Reference Citation Analysis]
340 MacMillan CJ, Furlong SJ, Doucette CD, Chen PL, Hoskin DW, Easton AS. Bevacizumab diminishes experimental autoimmune encephalomyelitis by inhibiting spinal cord angiogenesis and reducing peripheral T-cell responses. J Neuropathol Exp Neurol 2012;71:983-99. [PMID: 23037326 DOI: 10.1097/NEN.0b013e3182724831] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
341 Roskoski R Jr. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun 2007;356:323-8. [PMID: 17367763 DOI: 10.1016/j.bbrc.2007.02.156] [Cited by in Crossref: 262] [Cited by in F6Publishing: 248] [Article Influence: 17.5] [Reference Citation Analysis]
342 Ware AD, Brewer N, Meyers C, Morris C, McCarthy E, Shore EM, James AW. Differential Vascularity in Genetic and Nonhereditary Heterotopic Ossification. Int J Surg Pathol 2019;27:859-67. [PMID: 31250694 DOI: 10.1177/1066896919857135] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
343 Comamala G, Wagner C, de la Torre PS, Jakobsen RU, Hilger M, Brouwer H, Rand KD. Hydrogen/deuterium exchange mass spectrometry with improved electrochemical reduction enables comprehensive epitope mapping of a therapeutic antibody to the cysteine-knot containing vascular endothelial growth factor. Analytica Chimica Acta 2020;1115:41-51. [DOI: 10.1016/j.aca.2020.04.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
344 Wu X, Jeong EK, Emerson L, Hoffman J, Parker DL, Lu ZR. Noninvasive evaluation of antiangiogenic effect in a mouse tumor model by DCE-MRI with Gd-DTPA cystamine copolymers. Mol Pharm. 2010;7:41-48. [PMID: 19958031 DOI: 10.1021/mp900153f] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
345 Fischer C, Schneider M, Carmeliet P. Principles and therapeutic implications of angiogenesis, vasculogenesis and arteriogenesis. Handb Exp Pharmacol 2006;:157-212. [PMID: 16999228 DOI: 10.1007/3-540-36028-x_6] [Cited by in Crossref: 57] [Cited by in F6Publishing: 36] [Article Influence: 3.8] [Reference Citation Analysis]
346 Farajpour Z, Rahbarizadeh F, Kazemi B, Ahmadvand D, Mohaghegh M. Identification and In Vitro Characterization of Phage-Displayed VHHs Targeting VEGF. J Biomol Screen 2014;19:547-55. [DOI: 10.1177/1087057113514275] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
347 Karalezli A, Kucukerdonmez C, Akova YA, Koktekir BE. Does topical bevacizumab prevent postoperative recurrence after pterygium surgery with conjunctival autografting? Int J Ophthalmol 2014;7:512-6. [PMID: 24967201 DOI: 10.3980/j.issn.2222-3959.2014.03.23] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
348 Laschke M, Menger M. Anti-angiogenic treatment strategies for the therapy of endometriosis. Human Reproduction Update 2012;18:682-702. [DOI: 10.1093/humupd/dms026] [Cited by in Crossref: 98] [Cited by in F6Publishing: 83] [Article Influence: 9.8] [Reference Citation Analysis]
349 Zahra FT, Sajib MS, Mikelis CM. Role of bFGF in Acquired Resistance upon Anti-VEGF Therapy in Cancer. Cancers (Basel) 2021;13:1422. [PMID: 33804681 DOI: 10.3390/cancers13061422] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
350 Maier KE, Levy M. From selection hits to clinical leads: progress in aptamer discovery. Mol Ther Methods Clin Dev 2016;5:16014. [PMID: 27088106 DOI: 10.1038/mtm.2016.14] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 9.7] [Reference Citation Analysis]
351 Park JE, Tan HS, Datta A, Lai RC, Zhang H, Meng W, Lim SK, Sze SK. Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Mol Cell Proteomics. 2010;9:1085-1099. [PMID: 20124223 DOI: 10.1074/mcp.m900381-mcp200] [Cited by in Crossref: 339] [Cited by in F6Publishing: 212] [Article Influence: 28.3] [Reference Citation Analysis]
352 Alfarouk KO, Ahmed SBM, Ahmed A, Elliott RL, Ibrahim ME, Ali HS, Wales CC, Nourwali I, Aljarbou AN, Bashir AHH, Alhoufie STS, Alqahtani SS, Cardone RA, Fais S, Harguindey S, Reshkin SJ. The Interplay of Dysregulated pH and Electrolyte Imbalance in Cancer. Cancers (Basel) 2020;12:E898. [PMID: 32272658 DOI: 10.3390/cancers12040898] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
353 Vergallo C, Hafeez MN, Iannotta D, Santos HA, D'Avanzo N, Dini L, Cilurzo F, Fresta M, Di Marzio L, Christian C. Conventional Nanosized Drug Delivery Systems for Cancer Applications. Adv Exp Med Biol 2021;1295:3-27. [PMID: 33543453 DOI: 10.1007/978-3-030-58174-9_1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
354 Muller AJ, Scherle PA. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer 2006;6:613-25. [PMID: 16862192 DOI: 10.1038/nrc1929] [Cited by in Crossref: 183] [Cited by in F6Publishing: 158] [Article Influence: 11.4] [Reference Citation Analysis]
355 Wang Y, Chen W, Shi Y, Yan C, Kong Z, Wang Y, Wang Y, Ma W. Imposing Phase II and Phase III Clinical Trials of Targeted Drugs for Glioblastoma: Current Status and Progress. Front Oncol 2021;11:719623. [PMID: 34568049 DOI: 10.3389/fonc.2021.719623] [Reference Citation Analysis]
356 Rodríguez Garzotto A, Díaz-García CV, Agudo-López A, Prieto García E, Ponce S, López-Martín JA, Paz-Ares L, Iglesias L, Agulló-Ortuño MT. Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer. Med Oncol 2016;33:105. [PMID: 27568331 DOI: 10.1007/s12032-016-0824-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
357 Hwang C, Marini S, Huber AK, Stepien DM, Sorkin M, Loder S, Pagani CA, Li J, Visser ND, Vasquez K, Garada MA, Li S, Xu J, Hsu CY, Yu PB, James AW, Mishina Y, Agarwal S, Li J, Levi B. Mesenchymal VEGFA induces aberrant differentiation in heterotopic ossification. Bone Res 2019;7:36. [PMID: 33293508 DOI: 10.1038/s41413-019-0075-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
358 Tyagi P, Barros M, Stansbury JW, Kompella UB. Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab. Mol Pharm 2013;10:2858-67. [PMID: 23734705 DOI: 10.1021/mp300716t] [Cited by in Crossref: 67] [Cited by in F6Publishing: 60] [Article Influence: 7.4] [Reference Citation Analysis]
359 Yuksel H, Yilmaz O, Karaman M, Bagriyanik HA, Firinci F, Kiray M, Turkeli A, Karaman O. Role of vascular endothelial growth factor antagonism on airway remodeling in asthma. Ann Allergy Asthma Immunol 2013;110:150-5. [PMID: 23548522 DOI: 10.1016/j.anai.2012.12.015] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
360 Tasoulas J, Tsourouflis G, Theocharis S. Neovascularization: an attractive but tricky target in thyroid cancer. Expert Opinion on Therapeutic Targets 2018;22:799-810. [DOI: 10.1080/14728222.2018.1513494] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
361 Mahmoud MM, Afifi MM. Anti-angiogenic therapy (bevacizumab) in the management of oral lichen planus. Eur J Oral Sci 2016;124:119-26. [PMID: 26892241 DOI: 10.1111/eos.12251] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
362 Wilson PM, LaBonte MJ, Lenz HJ. Assessing the in vivo efficacy of biologic antiangiogenic therapies. Cancer Chemother Pharmacol. 2013;71:1-12. [PMID: 23053262 DOI: 10.1007/s00280-012-1978-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
363 Chui J, Girolamo ND, Wakefield D, Coroneo MT. The Pathogenesis of Pterygium: Current Concepts and Their Therapeutic Implications. The Ocular Surface 2008;6:24-43. [DOI: 10.1016/s1542-0124(12)70103-9] [Cited by in Crossref: 109] [Cited by in F6Publishing: 58] [Article Influence: 7.8] [Reference Citation Analysis]
364 Takakusagi Y, Takakusagi K, Ida N, Takami M, Matsumoto Y, Kusayanagi T, Nakabayashi T, Aoki S, Murata H, Ohta K, Sugawara F, Sakaguchi K. Binding region and interaction properties of sulfoquinovosylacylglycerol (SQAG) with human vascular endothelial growth factor 165 revealed by biosensor-based assays. Med Chem Commun 2011;2:1188. [DOI: 10.1039/c1md00180a] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
365 Smirnoff P, Roiz L, Angelkovitch B, Schwartz B, Shoseyov O. A recombinant human RNASET2 glycoprotein with antitumorigenic and antiangiogenic characteristics: Expression, purification, and characterization. Cancer 2006;107:2760-9. [DOI: 10.1002/cncr.22327] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 2.8] [Reference Citation Analysis]
366 Watanabe M, Boyer JL, Crystal RG. AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors. Gene Ther 2010;17:1042-51. [PMID: 20596059 DOI: 10.1038/gt.2010.87] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
367 Lee SH, Leem HS, Jeong SM, Lee K. Bevacizumab accelerates corneal wound healing by inhibiting TGF-beta2 expression in alkali-burned mouse cornea. BMB Rep 2009;42:800-5. [PMID: 20044951 DOI: 10.5483/bmbrep.2009.42.12.800] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
368 Pinchuk B, Horbert R, Döbber A, Kuhl L, Peifer C. Photoactivatable Caged Prodrugs of VEGFR-2 Kinase Inhibitors. Molecules 2016;21:E570. [PMID: 27136525 DOI: 10.3390/molecules21050570] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
369 Lee DH, Lee MY, Seo Y, Hong HJ, An HJ, Kang JS, Kim HM. Multi-paratopic VEGF decoy receptor have superior anti-tumor effects through anti-EGFRs and targeted anti-angiogenic activities. Biomaterials 2018;171:34-45. [PMID: 29679794 DOI: 10.1016/j.biomaterials.2018.04.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
370 Tessitore A, Cicciarelli G, Del Vecchio F, Gaggiano A, Verzella D, Fischietti M, Vecchiotti D, Capece D, Zazzeroni F, Alesse E. MicroRNAs in the DNA Damage/Repair Network and Cancer. Int J Genomics. 2014;2014:820248. [PMID: 24616890 DOI: 10.1155/2014/820248] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 5.9] [Reference Citation Analysis]
371 Li R, Chen X, You Y, Wang X, Liu Y, Hu Q, Yan W. Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics. Oncotarget 2015;6:30968-74. [PMID: 26427041 DOI: 10.18632/oncotarget.5038] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
372 Sousa F, Costa-Pereira AI, Cruz A, Ferreira FJ, Gouveia M, Bessa J, Sarmento B, Travasso RDM, Mendes Pinto I. Intratumoral VEGF nanotrapper reduces gliobastoma vascularization and tumor cell mass. J Control Release 2021;339:381-90. [PMID: 34592385 DOI: 10.1016/j.jconrel.2021.09.031] [Reference Citation Analysis]
373 Papapetropoulos A. A ginseng-derived oestrogen receptor beta (ERbeta) agonist, Rb1 ginsenoside, attenuates capillary morphogenesis. Br J Pharmacol 2007;152:172-4. [PMID: 17603551 DOI: 10.1038/sj.bjp.0707360] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
374 Qi N, Li F, Li X, Kang H, Zhao H, Du N. Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion. Medicine (Baltimore) 2016;95:e5392. [PMID: 27893676 DOI: 10.1097/MD.0000000000005392] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
375 Hammoud L, Adams JR, Loch AJ, Marcellus RC, Uehling DE, Aman A, Fladd C, McKee TD, Jo CEB, Al-Awar R, Egan SE, Rossant J. Identification of RSK and TTK as Modulators of Blood Vessel Morphogenesis Using an Embryonic Stem Cell-Based Vascular Differentiation Assay. Stem Cell Reports 2016;7:787-801. [PMID: 27618721 DOI: 10.1016/j.stemcr.2016.08.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
376 Berger S, Dyugovskaya L, Polyakov A, Lavie L. Short-term fibronectin treatment induces endothelial-like and angiogenic properties in monocyte-derived immature dendritic cells: Involvement of intracellular VEGF and MAPK regulation. European Journal of Cell Biology 2012;91:640-53. [DOI: 10.1016/j.ejcb.2012.02.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
377 Tsukamoto I, Sakakibara N, Maruyama T, Igarashi J, Kosaka H, Kubota Y, Tokuda M, Ashino H, Hattori K, Tanaka S, Kawata M, Konishi R. A novel nucleic acid analogue shows strong angiogenic activity. Biochemical and Biophysical Research Communications 2010;399:699-704. [DOI: 10.1016/j.bbrc.2010.08.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
378 Lebrun H, Turpin A, Zerbib P. Therapeutic implications of B-RAF mutations in colorectal cancer. J Visc Surg 2021:S1878-7886(21)00059-X. [PMID: 33975809 DOI: 10.1016/j.jviscsurg.2021.04.002] [Reference Citation Analysis]
379 Hassan-Mohamed I, Giorgio C, Incerti M, Russo S, Pala D, Pasquale EB, Zanotti I, Vicini P, Barocelli E, Rivara S, Mor M, Lodola A, Tognolini M. UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. Br J Pharmacol 2014;171:5195-208. [PMID: 24597515 DOI: 10.1111/bph.12669] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
380 Ozgurhan EB, Agca A, Kara N, Yuksel K, Demircan A, Demirok A. Topical Application of Bevacizumab as an Adjunct to Recurrent Pterygium Surgery. Cornea 2013;32:835-8. [DOI: 10.1097/ico.0b013e3182772d4e] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
381 Wilting J, Becker J. Two endothelial cell lines derived from the somite. Anat Embryol (Berl) 2006;211 Suppl 1:57-63. [PMID: 17047989 DOI: 10.1007/s00429-006-0120-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
382 Doctor PP, Bhat PV, Foster CS. Subconjunctival bevacizumab for corneal neovascularization. Cornea 2008;27:992-5. [PMID: 18812760 DOI: 10.1097/ICO.0b013e31817786ad] [Cited by in Crossref: 51] [Cited by in F6Publishing: 12] [Article Influence: 3.6] [Reference Citation Analysis]
383 Molhoek KR, Shada AL, Smolkin M, Chowbina S, Papin J, Brautigan DL, Slingluff CL Jr. Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R. Melanoma Res 2011;21:274-84. [PMID: 21654344 DOI: 10.1097/CMR.0b013e328343a1d6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
384 Lee S, Kim S, Koo DJ, Yu J, Cho H, Lee H, Song JM, Kim SY, Min DH, Jeon NL. 3D Microfluidic Platform and Tumor Vascular Mapping for Evaluating Anti-Angiogenic RNAi-Based Nanomedicine. ACS Nano 2021;15:338-50. [PMID: 33231435 DOI: 10.1021/acsnano.0c05110] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
385 Escudier B, Cosaert J, Jethwa S. Targeted therapies in the management of renal cell carcinoma: role of bevacizumab. Biologics 2008;2:517-30. [PMID: 19707382 DOI: 10.2147/btt.s3509] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
386 Bayat M, Asemani Y, Mohammadi MR, Sanaei M, Namvarpour M, Eftekhari R. An overview of some potential immunotherapeutic options against COVID-19. Int Immunopharmacol 2021;95:107516. [PMID: 33765610 DOI: 10.1016/j.intimp.2021.107516] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
387 Ulivi P, Marisi G, Passardi A. Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer. Oncotarget 2016;7:46678-91. [PMID: 27081084 DOI: 10.18632/oncotarget.8712] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
388 Tsang CM, Cheung KC, Cheung YC, Man K, Lui VW, Tsao SW, Feng Y. Berberine suppresses Id-1 expression and inhibits the growth and development of lung metastases in hepatocellular carcinoma. Biochim Biophys Acta. 2015;1852:541-551. [PMID: 25496992 DOI: 10.1016/j.bbadis.2014.12.004] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 6.5] [Reference Citation Analysis]
389 Jeltsch M, Leppänen VM, Saharinen P, Alitalo K. Receptor tyrosine kinase-mediated angiogenesis. Cold Spring Harb Perspect Biol 2013;5:a009183. [PMID: 24003209 DOI: 10.1101/cshperspect.a009183] [Cited by in Crossref: 96] [Cited by in F6Publishing: 91] [Article Influence: 10.7] [Reference Citation Analysis]
390 Zhang MY, Lu JJ, Wang L, Gao ZC, Hu H, Ung CO, Wang YT. Development of monoclonal antibodies in China: overview and prospects. Biomed Res Int 2015;2015:168935. [PMID: 25811022 DOI: 10.1155/2015/168935] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
391 Witz IP, Levy-Nissenbaum O. The tumor microenvironment in the post-PAGET era. Cancer Lett. 2006;242:1-10. [PMID: 16413116 DOI: 10.1016/j.canlet.2005.12.005] [Cited by in Crossref: 94] [Cited by in F6Publishing: 85] [Article Influence: 5.9] [Reference Citation Analysis]
392 Zhou F, Lu X, Zhang X. Serum miR-30c Level Predicted Cardiotoxicity in Non-small Cell Lung Cancer Patients Treated with Bevacizumab. Cardiovasc Toxicol 2018;18:284-9. [PMID: 29737469 DOI: 10.1007/s12012-018-9457-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
393 Kazemi-Lomedasht F, Behdani M, Bagheri KP, Habibi-Anbouhi M, Abolhassani M, Arezumand R, Shahbazzadeh D, Mirzahoseini H. Inhibition of angiogenesis in human endothelial cell using VEGF specific nanobody. Mol Immunol 2015;65:58-67. [PMID: 25645505 DOI: 10.1016/j.molimm.2015.01.010] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 5.6] [Reference Citation Analysis]
394 Yamada T, Saito T, Hill Y, Shimizu Y, Tsukakoshi K, Mizuno H, Hayashi H, Ikebukuro K, Toyo'oka T, Todoroki K. High-Throughput Bioanalysis of Bevacizumab in Human Plasma Based on Enzyme-Linked Aptamer Assay Using Anti-Idiotype DNA Aptamer. Anal Chem 2019;91:3125-30. [PMID: 30667211 DOI: 10.1021/acs.analchem.8b05725] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
395 Yang RF, Yu B, Zhang RQ, Wang XH, Li C, Wang P, Zhang Y, Han B, Gao XX, Zhang L, Jiang ZM. Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer. Braz J Med Biol Res 2017;51:e6073. [PMID: 29185589 DOI: 10.1590/1414-431X20176073] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
396 Zhu C, Ren X, Liu D, Zhang C. Oxaliplatin-induced hepatic sinusoidal obstruction syndrome. Toxicology 2021;460:152882. [PMID: 34352347 DOI: 10.1016/j.tox.2021.152882] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
397 Hall WA, Pugh SL, Wefel JS, Armstrong TS, Gilbert MR, Brachman DG, Werner-Wasik M, Wendland MM, Brown PD, Chao ST, Roof KS, Robins HI, Mehta MP, Curran WJ Jr, Movsas B. Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes. Neurosurgery 2019;84:66-76. [PMID: 29618054 DOI: 10.1093/neuros/nyy003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
398 Maehara H, Kaname T, Yanagi K, Hanzawa H, Owan I, Kinjou T, Kadomatsu K, Ikematsu S, Iwamasa T, Kanaya F. Midkine as a novel target for antibody therapy in osteosarcoma. Biochem Biophys Res Commun. 2007;358:757-762. [PMID: 17506984 DOI: 10.1016/j.bbrc.2007.04.183] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
399 Grisanti S, Ziemssen F. Bevacizumab: off-label use in ophthalmology. Indian J Ophthalmol 2007;55:417-20. [PMID: 17951896 DOI: 10.4103/0301-4738.36474] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
400 Galun D, Mijac D, Filipovic A, Bogdanovic A, Zivanovic M, Masulovic D. Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective. JPM 2022;12:149. [DOI: 10.3390/jpm12020149] [Reference Citation Analysis]
401 Lim JI. Macular degeneration: the latest in current medical management. Retina 2006;26:S17-20. [PMID: 16832293 DOI: 10.1097/01.iae.0000236455.00770.47] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
402 Dong J, Song L, Yin J, He W, Wu Y, Gu N, Zhang Y. Co 3 O 4 Nanoparticles with Multi-Enzyme Activities and Their Application in Immunohistochemical Assay. ACS Appl Mater Interfaces 2014;6:1959-70. [DOI: 10.1021/am405009f] [Cited by in Crossref: 214] [Cited by in F6Publishing: 168] [Article Influence: 26.8] [Reference Citation Analysis]
403 Ulbrich K, Holá K, Šubr V, Bakandritsos A, Tuček J, Zbořil R. Targeted Drug Delivery with Polymers and Magnetic Nanoparticles: Covalent and Noncovalent Approaches, Release Control, and Clinical Studies. Chem Rev 2016;116:5338-431. [DOI: 10.1021/acs.chemrev.5b00589] [Cited by in Crossref: 872] [Cited by in F6Publishing: 723] [Article Influence: 145.3] [Reference Citation Analysis]
404 Omar AI. Bevacizumab for the treatment of surgically unresectable cervical cord hemangioblastoma: a case report. J Med Case Rep 2012;6:238. [PMID: 22883663 DOI: 10.1186/1752-1947-6-238] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
405 Abbassy M, Missios S, Barnett GH, Brewer C, Peereboom DM, Ahluwalia M, Neyman G, Chao ST, Suh JH, Vogelbaum MA. Phase I Trial of Radiosurgery Dose Escalation Plus Bevacizumab in Patients With Recurrent/Progressive Glioblastoma. Neurosurgery 2018;83:385-92. [PMID: 28973311 DOI: 10.1093/neuros/nyx369] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
406 Ren Y, Fleischmann D, Foygel K, Molvin L, Lutz AM, Koong AC, Jeffrey RB, Tian L, Willmann JK. Antiangiogenic and radiation therapy: early effects on in vivo computed tomography perfusion parameters in human colon cancer xenografts in mice. Invest Radiol. 2012;47:25-32. [PMID: 22178893 DOI: 10.1097/rli.0b013e31823a82f6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
407 Shang B, Cao Z, Zhou Q. Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives. Front Med 2012;6:67-78. [DOI: 10.1007/s11684-012-0176-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
408 Yadav VN, Altshuler D, Kadiyala P, Zamler D, Comba A, Appelman H, Dunn P, Koschmann C, Castro MG, Löwenstein PR. Molecular ablation of tumor blood vessels inhibits therapeutic effects of radiation and bevacizumab. Neuro Oncol 2018;20:1356-67. [PMID: 29660022 DOI: 10.1093/neuonc/noy055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
409 Tarallo V, Lepore L, Marcellini M, Dal Piaz F, Tudisco L, Ponticelli S, Lund FW, Roepstorff P, Orlandi A, Pisano C, De Tommasi N, De Falco S. The biflavonoid amentoflavone inhibits neovascularization preventing the activity of proangiogenic vascular endothelial growth factors. J Biol Chem 2011;286:19641-51. [PMID: 21471210 DOI: 10.1074/jbc.M110.186239] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
410 Pedersen KB, Møller F, Sjølie AK, Andréasson S. ELECTROPHYSIOLOGICAL ASSESSMENT OF RETINAL FUNCTION DURING 6 MONTHS OF BEVACIZUMAB TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina 2010;30:1025-33. [DOI: 10.1097/iae.0b013e3181cafc8f] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
411 Al-Latayfeh M, Silva PS, Sun JK, Aiello LP. Antiangiogenic therapy for ischemic retinopathies. Cold Spring Harb Perspect Med 2012;2:a006411. [PMID: 22675660 DOI: 10.1101/cshperspect.a006411] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
412 Chen CW, Yang CH, Lin YH, Hou YC, Cheng TJ, Chang ST, Huang YH, Chung ST, Chio CC, Shan YS, Cheng HC, Chang WT. The Fibronectin Expression Determines the Distinct Progressions of Malignant Gliomas via Transforming Growth Factor-Beta Pathway. Int J Mol Sci 2021;22:3782. [PMID: 33917452 DOI: 10.3390/ijms22073782] [Reference Citation Analysis]
413 Trevisan França de Lima L, Broszczak D, Zhang X, Bridle K, Crawford D, Punyadeera C. The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma. Biochim Biophys Acta Rev Cancer 2020;1874:188451. [PMID: 33065194 DOI: 10.1016/j.bbcan.2020.188451] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
414 Perry BN, Arbiser JL. The duality of angiogenesis: implications for therapy of human disease. J Invest Dermatol. 2006;126:2160-2166. [PMID: 16983325 DOI: 10.1038/sj.jid.5700462] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
415 Gwak SJ, Che L, Yun Y, Lee M, Ha Y. Combination Therapy by Tissue-Specific Suicide Gene and Bevacizumab in Intramedullary Spinal Cord Tumor. Yonsei Med J 2020;61:1042-9. [PMID: 33251778 DOI: 10.3349/ymj.2020.61.12.1042] [Reference Citation Analysis]
416 Crist AM, Lee AR, Patel NR, Westhoff DE, Meadows SM. Vascular deficiency of Smad4 causes arteriovenous malformations: a mouse model of Hereditary Hemorrhagic Telangiectasia. Angiogenesis 2018;21:363-80. [PMID: 29460088 DOI: 10.1007/s10456-018-9602-0] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 11.0] [Reference Citation Analysis]
417 Haßel SK, Mayer G. Aptamers as Therapeutic Agents: Has the Initial Euphoria Subsided? Mol Diagn Ther 2019;23:301-9. [PMID: 31037641 DOI: 10.1007/s40291-019-00400-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
418 Pore N, Gupta AK, Cerniglia GJ, Maity A. HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells. Neoplasia 2006;8:889-95. [PMID: 17132220 DOI: 10.1593/neo.06535] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 3.4] [Reference Citation Analysis]
419 Tao X, Huang Y, Li R, Qing R, Ma L, Rhodus NL, Cheng B. Assessment of local angiogenesis and vascular endothelial growth factor in the patients with atrophic-erosive and reticular oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103:661-9. [PMID: 17306572 DOI: 10.1016/j.tripleo.2006.05.023] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 2.5] [Reference Citation Analysis]
420 Zou L, Lai H, Zhou Q, Xiao F. Lasting controversy on ranibizumab and bevacizumab. Theranostics 2011;1:395-402. [PMID: 22211145 DOI: 10.7150/thno/v01p0395] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
421 Duyndam MC, van Berkel MP, Dorsman JC, Rockx DA, Pinedo HM, Boven E. Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells. Biochemical Pharmacology 2007;74:191-201. [DOI: 10.1016/j.bcp.2007.04.003] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 3.1] [Reference Citation Analysis]
422 Aravantinos G, Pectasides D. Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review. J Ovarian Res 2014;7:57. [PMID: 24864163 DOI: 10.1186/1757-2215-7-57] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 4.5] [Reference Citation Analysis]
423 Yan TL, Bai LF, Zhu HL, Zhang WM, Lv PC. Synthesis and Biological Evaluation of Glycyrrhetic Acid Derivatives as Potential VEGFR2 Inhibitors. ChemMedChem 2017;12:1087-96. [PMID: 28599090 DOI: 10.1002/cmdc.201700271] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
424 Jaishuen A, Berrios-Rivera JP, Sirisabya N, Zheng HG, Li Y, Kavanagh JJ. Erosive osteoarthritis during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous carcinoma of the ovary. Int J Gynecol Cancer 2008;18:379-83. [PMID: 17624988 DOI: 10.1111/j.1525-1438.2007.01023.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
425 Paramashivam SK, Elayaperumal K, Natarajan BB, Ramamoorthy MD, Balasubramanian S, Dhiraviam KN. In silico pharmacokinetic and molecular docking studies of small molecules derived from Indigofera aspalathoides Vahl targeting receptor tyrosine kinases. Bioinformation 2015;11:73-84. [PMID: 25848167 DOI: 10.6026/97320630011073] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
426 Perrone MG, Luisi O, De Grassi A, Ferorelli S, Cormio G, Scilimati A. Translational Theragnosis of Ovarian Cancer: where do we stand? Curr Med Chem 2020;27:5675-715. [PMID: 31419925 DOI: 10.2174/0929867326666190816232330] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
427 Tang YC, Zhang Y, Zhou J, Zhi Q, Wu MY, Gong FR, Shen M, Liu L, Tao M, Shen B, Gu DM, Yu J, Xu MD, Gao Y, Li W. Ginsenoside Rg3 targets cancer stem cells and tumor angiogenesis to inhibit colorectal cancer progression in vivo. Int J Oncol 2018;52:127-38. [PMID: 29115601 DOI: 10.3892/ijo.2017.4183] [Cited by in Crossref: 15] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
428 Masoumi Moghaddam S, Amini A, Morris DL, Pourgholami MH. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev 2012;31:143-62. [PMID: 22101807 DOI: 10.1007/s10555-011-9337-5] [Cited by in Crossref: 110] [Cited by in F6Publishing: 98] [Article Influence: 11.0] [Reference Citation Analysis]
429 Rao L, De Veirman K, Giannico D, Saltarella I, Desantis V, Frassanito MA, Solimando AG, Ribatti D, Prete M, Harstrick A, Fiedler U, De Raeve H, Racanelli V, Vanderkerken K, Vacca A. Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin® protein MP0250: a preclinical study. Oncotarget 2018;9:13366-81. [PMID: 29568363 DOI: 10.18632/oncotarget.24351] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
430 Homs MY, Voest EE, Siersema PD. Emerging drugs for esophageal cancer. Expert Opin Emerg Drugs 2009;14:329-39. [PMID: 19453287 DOI: 10.1517/14728210902976842] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
431 Sessa C, Guibal A, Del Conte G, Rüegg C. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat Rev Clin Oncol 2008;5:378-91. [DOI: 10.1038/ncponc1150] [Cited by in Crossref: 113] [Cited by in F6Publishing: 88] [Article Influence: 8.1] [Reference Citation Analysis]
432 Lee J, Lee J, Yu H, Choi K, Choi C. Differential dependency of human cancer cells on vascular endothelial growth factor-mediated autocrine growth and survival. Cancer Letters 2011;309:145-50. [DOI: 10.1016/j.canlet.2011.05.026] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
433 Mirshojaei SF, Ahmadi A, Morales-avila E, Ortiz-reynoso M, Reyes-perez H. Radiolabelled nanoparticles: novel classification of radiopharmaceuticals for molecular imaging of cancer. Journal of Drug Targeting 2016;24:91-101. [DOI: 10.3109/1061186x.2015.1048516] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
434 Khalili H, Sharma G, Froome A, Khaw PT, Brocchini S. Storage stability of bevacizumab in polycarbonate and polypropylene syringes. Eye (Lond) 2015;29:820-7. [PMID: 25853399 DOI: 10.1038/eye.2015.28] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
435 Zadorozhna M, Di Gioia S, Conese M, Mangieri D. Neovascularization is a key feature of liver fibrosis progression: anti-angiogenesis as an innovative way of liver fibrosis treatment. Mol Biol Rep 2020;47:2279-88. [PMID: 32040707 DOI: 10.1007/s11033-020-05290-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
436 Hosseini H, Nowroozzadeh MH, Salouti R, Nejabat M. Anti-VEGF therapy with bevacizumab for anterior segment eye disease. Cornea 2012;31:322-34. [PMID: 22157572 DOI: 10.1097/ICO.0b013e31822480f9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
437 Barney BM, Markovic SN, Laack NN, Miller RC, Sarkaria JN, Macdonald OK, Bauer HJ, Olivier KR. Increased Bowel Toxicity in Patients Treated With a Vascular Endothelial Growth Factor Inhibitor (VEGFI) After Stereotactic Body Radiation Therapy (SBRT). International Journal of Radiation Oncology*Biology*Physics 2013;87:73-80. [DOI: 10.1016/j.ijrobp.2013.05.012] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 6.9] [Reference Citation Analysis]
438 Solano JM, Bakri SJ, Pulido JS. Regression of radiation-induced macular edema after systemic bevacizumab. Can J Ophthalmol 2007;42:748-9. [PMID: 17823640 DOI: 10.3129/i07-140] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
439 Kong GM, Zhang XR, Wu KY, Zhao FY, Zhu HH, Zhang XD, Liao YX, Bo P. Inhibitory effect of KDR-specific monoclonal antibody on tumor growth in nude mice bearing human gastric cancer. Shijie Huaren Xiaohua Zazhi 2011; 19(28): 2925-2930 [DOI: 10.11569/wcjd.v19.i28.2925] [Reference Citation Analysis]
440 Monk KA, Siles R, Hadimani MB, Mugabe BE, Ackley JF, Studerus SW, Edvardsen K, Trawick ML, Garner CM, Rhodes MR, Pettit GR, Pinney KG. Design, synthesis, and biological evaluation of combretastatin nitrogen-containing derivatives as inhibitors of tubulin assembly and vascular disrupting agents. Bioorganic & Medicinal Chemistry 2006;14:3231-44. [DOI: 10.1016/j.bmc.2005.12.033] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 3.6] [Reference Citation Analysis]
441 Jiang X, Engelbach JA, Yuan L, Cates J, Gao F, Drzymala RE, Hallahan DE, Rich KM, Schmidt RE, Ackerman JJ, Garbow JR. Anti-VEGF antibodies mitigate the development of radiation necrosis in mouse brain. Clin Cancer Res 2014;20:2695-702. [PMID: 24647570 DOI: 10.1158/1078-0432.CCR-13-1941] [Cited by in Crossref: 51] [Cited by in F6Publishing: 31] [Article Influence: 6.4] [Reference Citation Analysis]
442 Fan Q, Wang X, Zhang H, Li C, Fan J, Xu J. Silencing cathepsin S gene expression inhibits growth, invasion and angiogenesis of human hepatocellular carcinoma in vitro. Biochem Biophys Res Commun. 2012;425:703-710. [PMID: 22796222 DOI: 10.1016/j.bbrc.2012.07.013] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
443 Chernoguz A, Crawford K, Vandersall A, Rao M, Willson T, Denson LA, Frischer JS. Pretreatment with anti-VEGF therapy may exacerbate inflammation in experimental acute colitis. J Pediatr Surg 2012;47:347-54. [PMID: 22325388 DOI: 10.1016/j.jpedsurg.2011.11.028] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
444 Lucena-Cacace A, Umeda M, Navas LE, Carnero A. NAMPT as a Dedifferentiation-Inducer Gene: NAD+ as Core Axis for Glioma Cancer Stem-Like Cells Maintenance. Front Oncol 2019;9:292. [PMID: 31119097 DOI: 10.3389/fonc.2019.00292] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
445 Miyake T, Kumasawa K, Sato N, Takiuchi T, Nakamura H, Kimura T. Soluble VEGF receptor 1 (sFLT1) induces non-apoptotic death in ovarian and colorectal cancer cells. Sci Rep 2016;6:24853. [PMID: 27103202 DOI: 10.1038/srep24853] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
446 Roskoski R. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol. 2007;62:179-213. [PMID: 17324579 DOI: 10.1016/j.critrevonc.2007.01.006] [Cited by in Crossref: 397] [Cited by in F6Publishing: 364] [Article Influence: 26.5] [Reference Citation Analysis]
447 Gutbrodt KL, Schliemann C, Giovannoni L, Frey K, Pabst T, Klapper W, Berdel WE, Neri D. Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia. Sci Transl Med 2013;5:201ra118. [PMID: 24005158 DOI: 10.1126/scitranslmed.3006221] [Cited by in Crossref: 84] [Cited by in F6Publishing: 74] [Article Influence: 10.5] [Reference Citation Analysis]
448 Enseleit F, Michels S, Sudano I, Stahel M, Zweifel S, Schlager O, Becker M, Winnik S, Nägele M, Flammer AJ, Neidhart M, Graf N, Matter CM, Seifert B, Lüscher TF, Ruschitzka F. SAVE-AMD: Safety of VEGF Inhibitors in Age-Related Macular Degeneration. Ophthalmologica 2017;238:205-16. [PMID: 28866675 DOI: 10.1159/000478665] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
449 Sarac O, Demirel S, Oltulu R. Efficacy of intralesional bevacizumab administration in primary pterygium: a quantitative analysis. Eye Contact Lens 2014;40:46-50. [PMID: 24335454 DOI: 10.1097/ICL.0000000000000004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
450 Yeo-Teh NSL, Ito Y, Jha S. High-Risk Human Papillomaviral Oncogenes E6 and E7 Target Key Cellular Pathways to Achieve Oncogenesis. Int J Mol Sci 2018;19:E1706. [PMID: 29890655 DOI: 10.3390/ijms19061706] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 12.0] [Reference Citation Analysis]
451 Leguerney I, Lassau N, Koscielny S, Rodrigues M, Massard C, Rouffiac V, Benatsou B, Thalmensi J, Bawa O, Opolon P, Peronneau P, Roche A. Combining functional imaging and interstitial pressure measurements to evaluate two anti-angiogenic treatments. Invest New Drugs 2012;30:144-56. [DOI: 10.1007/s10637-010-9543-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
452 Mota SEH, Nuñez-solorio SM. Experience with Intravitreal Bevacizumab as a Preoperative Adjunct in 23-G Vitrectomy for Advanced Proliferative Diabetic Retinopathy. European Journal of Ophthalmology 2010;20:1047-52. [DOI: 10.1177/112067211002000604] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
453 Notara M, Lentzsch A, Clahsen T, Behboudifard S, Braun G, Cursiefen C. Bevacizumab Induces Upregulation of Keratin 3 and VEGFA in Human Limbal Epithelial Cells in Vitro. J Clin Med 2019;8:E1925. [PMID: 31717500 DOI: 10.3390/jcm8111925] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
454 Le HC, Lupu M, Kotedia K, Rosen N, Solit D, Koutcher JA. Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22r. Magn Reson Med 2009;62:1112-9. [PMID: 19780165 DOI: 10.1002/mrm.22137] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
455 Behaegel J, Ní Dhubhghaill S, Koppen C, Zakaria N. Safety of Cultivated Limbal Epithelial Stem Cell Transplantation for Human Corneal Regeneration. Stem Cells Int 2017;2017:6978253. [PMID: 28465692 DOI: 10.1155/2017/6978253] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
456 Zhang Y, He L, Meng L, Luo W, Xu X. Suppression of tumor-induced angiogenesis by taspine isolated from Radix et Rhizoma Leonticis and its mechanism of action in vitro. Cancer Letters 2008;262:103-13. [DOI: 10.1016/j.canlet.2007.11.035] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
457 Shaaban S, Alsulami M, Arbab SA, Ara R, Shankar A, Iskander A, Angara K, Jain M, Bagher-Ebadian H, Achyut BR, Arbab AS. Targeting Bone Marrow to Potentiate the Anti-Tumor Effect of Tyrosine Kinase Inhibitor in Preclinical Rat Model of Human Glioblastoma. Int J Cancer Res 2016;12:69-81. [PMID: 27429653 DOI: 10.3923/ijcr.2016.69.81] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
458 Gautier B, Goncalves V, Diana D, Di Stasi R, Teillet F, Lenoir C, Huguenot F, Garbay C, Fattorusso R, D'Andrea LD, Vidal M, Inguimbert N. Biochemical and structural analysis of the binding determinants of a vascular endothelial growth factor receptor peptidic antagonist. J Med Chem 2010;53:4428-40. [PMID: 20462213 DOI: 10.1021/jm1002167] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
459 Ring J, Persigehl T, Remmele S, Heindel W, Dahnke H, Bremer C. Monitoring of bevacizumab-induced antiangiogenic treatment effects by "steady state" ultrasmall superparamagnetic iron oxide particles magnetic resonance imaging using robust multiecho ΔR2* relaxometry. Invest Radiol 2011;46:326-30. [PMID: 21358548 DOI: 10.1097/RLI.0b013e3182045457] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
460 Kim DY, Choi JA, Koh JY, Yoon YH. Efficacy and safety of aflibercept in in vitro and in vivo models of retinoblastoma. J Exp Clin Cancer Res 2016;35:171. [PMID: 27814771 DOI: 10.1186/s13046-016-0451-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
461 Jirjees F, Soliman K, Wang Y, Sonawane R, Sheshala R, Jones D, Thakur RRS. A validated size exclusion chromatography method coupled with fluorescence detection for rapid quantification of bevacizumab in ophthalmic formulations. J Pharm Biomed Anal 2019;174:145-50. [PMID: 31167158 DOI: 10.1016/j.jpba.2019.05.038] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
462 Chen L, Yang X, Luo D, Yu W. Efficient Production of a Bioactive Bevacizumab Monoclonal Antibody Using the 2A Self-cleavage Peptide in Transgenic Rice Callus. Front Plant Sci 2016;7:1156. [PMID: 27555853 DOI: 10.3389/fpls.2016.01156] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
463 Mohamed Q, Wong TY. Emerging drugs for diabetic retinopathy. Expert Opinion on Emerging Drugs 2008;13:675-94. [DOI: 10.1517/14728210802584035] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
464 Zhao Y, Yao Q, Tan H, Wu B, Hu P, Wu P, Gu Y, Zhang C, Cheng D, Shi H. Design and preliminary assessment of 99mTc-labeled ultrasmall superparamagnetic iron oxide-conjugated bevacizumab for single photon emission computed tomography/magnetic resonance imaging of hepatocellular carcinoma. J Radioanal Nucl Chem 2014;299:1273-80. [DOI: 10.1007/s10967-013-2846-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
465 Vedakumari SW, Senthil R, Sekar S, Babu CS, Sastry TP. Enhancing anti-cancer activity of erlotinib by antibody conjugated nanofibrin - In vitro studies on lung adenocarcinoma cell lines. Materials Chemistry and Physics 2019;224:328-33. [DOI: 10.1016/j.matchemphys.2018.11.061] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
466 Katoh M. Therapeutics targeting angiogenesis: genetics and epigenetics, extracellular miRNAs and signaling networks (Review). Int J Mol Med. 2013;32:763-767. [PMID: 23863927 DOI: 10.3892/ijmm.2013.1444] [Cited by in Crossref: 85] [Cited by in F6Publishing: 83] [Article Influence: 9.4] [Reference Citation Analysis]
467 Kennedy DC, Coen B, Wheatley AM, McCullagh KJA. Microvascular Experimentation in the Chick Chorioallantoic Membrane as a Model for Screening Angiogenic Agents including from Gene-Modified Cells. Int J Mol Sci 2021;23:452. [PMID: 35008876 DOI: 10.3390/ijms23010452] [Reference Citation Analysis]
468 Pourgholami MH, Khachigian LM, Fahmy RG, Badar S, Wang L, Chu SW, Morris DL. Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesis. Biochem Biophys Res Commun 2010;397:729-34. [PMID: 20537982 DOI: 10.1016/j.bbrc.2010.06.019] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
469 Frangié C, Lefaucheur C, Medioni J, Jacquot C, Hill GS, Nochy D. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 2007;8:177-8. [PMID: 17267332 DOI: 10.1016/S1470-2045(07)70037-2] [Cited by in Crossref: 113] [Cited by in F6Publishing: 41] [Article Influence: 7.5] [Reference Citation Analysis]
470 Fangusaro J, Gururangan S, Jakacki RI, Kaste SC, Goldman S, Pollack IF, Boyett JM, Kun LE. Bevacizumab-associated osteonecrosis of the wrist and knee in three pediatric patients with recurrent CNS tumors. J Clin Oncol 2013;31:e24-7. [PMID: 23169504 DOI: 10.1200/JCO.2012.43.6733] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
471 Silva SR, Bowen KA, Rychahou PG, Jackson LN, Weiss HL, Lee EY, Townsend CM, Evers BM. VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis. Int J Cancer. 2011;128:1045-1056. [PMID: 20473929 DOI: 10.1002/ijc.25441] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 4.0] [Reference Citation Analysis]
472 Lewis AL, Holden RR, Chung ST, Czuczman P, Kuchel T, Finnie J, Porter S, Foster D. Feasibility, safety and pharmacokinetic study of hepatic administration of drug-eluting beads loaded with irinotecan (DEBIRI) followed by intravenous administration of irinotecan in a porcine model. J Mater Sci Mater Med 2013;24:115-27. [PMID: 23015264 DOI: 10.1007/s10856-012-4768-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
473 Kenney S, Vistica DT, Stockwin LH, Burkett S, Hollingshead MG, Borgel SD, Butcher DO, Schrump DS, Shoemaker RH. ASPS-1, a novel cell line manifesting key features of alveolar soft part sarcoma. J Pediatr Hematol Oncol 2011;33:360-8. [PMID: 21552147 DOI: 10.1097/MPH.0b013e3182002f9f] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
474 Rehman AO, Wang CY. Notch signaling in the regulation of tumor angiogenesis. Trends Cell Biol 2006;16:293-300. [PMID: 16697642 DOI: 10.1016/j.tcb.2006.04.003] [Cited by in Crossref: 73] [Cited by in F6Publishing: 74] [Article Influence: 4.6] [Reference Citation Analysis]
475 Hofmann T, Altmann K. Resorcylic acid lactones as new lead structures for kinase inhibition. Comptes Rendus Chimie 2008;11:1318-35. [DOI: 10.1016/j.crci.2008.06.010] [Cited by in Crossref: 56] [Cited by in F6Publishing: 42] [Article Influence: 4.0] [Reference Citation Analysis]
476 Liu F, Kc P, Ni L, Zhang G, Zhe J. A microfluidic competitive immuno-aggregation assay for high sensitivity cell secretome detection. Organogenesis 2018;14:67-81. [PMID: 29883244 DOI: 10.1080/15476278.2018.1461306] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
477 Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the "biological missile" for targeted cancer therapy. Signal Transduct Target Ther 2022;7:93. [PMID: 35318309 DOI: 10.1038/s41392-022-00947-7] [Reference Citation Analysis]
478 Ragab FAF, Abdel-Aziz SA, Kamel M, Ouf AMA, Allam HA. Design, synthesis and biological evaluation of some new 1,3,4-thiadiazine-thiourea derivatives as potential antitumor agents against non-small cell lung cancer cells. Bioorg Chem 2019;93:103323. [PMID: 31586713 DOI: 10.1016/j.bioorg.2019.103323] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
479 Morera Y, González R, Lamdan H, Pérez L, González Y, Agüero J, Castro J, Romero JC, Etchegoyen AY, Ayala M, Gavilondo JV. Vaccination with a mutated variant of human Vascular Endothelial Growth Factor (VEGF) blocks VEGF-induced retinal neovascularization in a rabbit experimental model. Exp Eye Res 2014;122:102-9. [PMID: 24675387 DOI: 10.1016/j.exer.2014.03.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
480 Parveen A, Subedi L, Kim HW, Khan Z, Zahra Z, Farooqi MQ, Kim SY. Phytochemicals Targeting VEGF and VEGF-Related Multifactors as Anticancer Therapy. J Clin Med 2019;8:E350. [PMID: 30871059 DOI: 10.3390/jcm8030350] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
481 Vistica DT, Hollingshead M, Borgel SD, Kenney S, Stockwin LH, Raffeld M, Schrump DS, Burkett S, Stone G, Butcher DO, Shoemaker RH. Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy. J Pediatr Hematol Oncol 2009;31:561-70. [PMID: 19636271 DOI: 10.1097/MPH.0b013e3181a6e043] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
482 Collet G, Lamerant-Fayel N, Tertil M, El Hafny-Rahbi B, Stepniewski J, Guichard A, Foucault-Collet A, Klimkiewicz K, Petoud S, Matejuk A, Grillon C, Jozkowicz A, Dulak J, Kieda C. Hypoxia-regulated overexpression of soluble VEGFR2 controls angiogenesis and inhibits tumor growth. Mol Cancer Ther 2014;13:165-78. [PMID: 24170768 DOI: 10.1158/1535-7163.MCT-13-0637] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
483 Fischer I, Cunliffe CH, Bollo RJ, Raza S, Monoky D, Chiriboga L, Parker EC, Golfinos JG, Kelly PJ, Knopp EA, Gruber ML, Zagzag D, Narayana A. High-grade glioma before and after treatment with radiation and Avastin: initial observations. Neuro Oncol 2008;10:700-8. [PMID: 18697955 DOI: 10.1215/15228517-2008-042] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 3.6] [Reference Citation Analysis]
484 Zhang L, Smith KM, Chong AL, Stempak D, Yeger H, Marrano P, Thorner PS, Irwin MS, Kaplan DR, Baruchel S. In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model. Neoplasia 2009;11:426-35. [PMID: 19412427 DOI: 10.1593/neo.09166] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 4.3] [Reference Citation Analysis]
485 Shoari A, Tahmasebi M, Khodabakhsh F, Cohan RA, Oghalaie A, Behdani M. Angiogenic biomolecules specific nanobodies application in cancer imaging and therapy; review and updates. International Immunopharmacology 2022;105:108585. [DOI: 10.1016/j.intimp.2022.108585] [Reference Citation Analysis]
486 Alves ACS, Bruinsmann FA, Guterres SS, Pohlmann AR. Organic Nanocarriers for Bevacizumab Delivery: An Overview of Development, Characterization and Applications. Molecules 2021;26:4127. [PMID: 34299401 DOI: 10.3390/molecules26144127] [Reference Citation Analysis]
487 Hager S, Fittler FJ, Wagner E, Bros M. Nucleic Acid-Based Approaches for Tumor Therapy. Cells 2020;9:E2061. [PMID: 32917034 DOI: 10.3390/cells9092061] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
488 Dınc E, Yıldırım O, Necat Yılmaz S, Canacankatan N, Ayaz L, Ozcan T, Temel GO. Intravitreal bevacizumab effects on VEGF levels in distant organs: an experimental study. Cutan Ocul Toxicol 2014;33:275-82. [PMID: 24228870 DOI: 10.3109/15569527.2013.855227] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
489 Coutts AS, Pires IM, Weston L, Buffa FM, Milani M, Li J, Harris AL, Hammond EM, La Thangue NB. Hypoxia-driven cell motility reflects the interplay between JMY and HIF-1α. Oncogene 2011;30:4835-42. [DOI: 10.1038/onc.2011.188] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
490 Mohammadpour M, Jabbarvand M, Delrish E, Khoshzaban A. Antiangiogenic effect of silicate nanoparticles on corneal neo-vascularisation induced by vascular endothelial growth factor. Journal of Medical Hypotheses and Ideas 2014;8:14-20. [DOI: 10.1016/j.jmhi.2013.06.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
491 Fu P, He YS, Huang Q, Ding T, Cen YC, Zhao HY, Wei X. Bevacizumab treatment for newly diagnosed glioblastoma: Systematic review and meta-analysis of clinical trials. Mol Clin Oncol 2016;4:833-8. [PMID: 27123291 DOI: 10.3892/mco.2016.816] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
492 Cai J, Hu M, Chen Z, Ling Z. The roles and mechanisms of hypoxia in liver fibrosis. J Transl Med 2021;19:186. [PMID: 33933107 DOI: 10.1186/s12967-021-02854-x] [Reference Citation Analysis]
493 Zhang DX, Vu LT, Ismail NN, Le MTN, Grimson A. Landscape of extracellular vesicles in the tumour microenvironment: Interactions with stromal cells and with non-cell components, and impacts on metabolic reprogramming, horizontal transfer of neoplastic traits, and the emergence of therapeutic resistance. Semin Cancer Biol 2021:S1044-579X(21)00013-4. [PMID: 33545339 DOI: 10.1016/j.semcancer.2021.01.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
494 Escudier B, Cosaert J, Pisa P. Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma. Expert Rev Anticancer Ther 2008;8:1545-57. [PMID: 18925847 DOI: 10.1586/14737140.8.10.1545] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
495 Sapiezynski J, Taratula O, Rodriguez-Rodriguez L, Minko T. Precision targeted therapy of ovarian cancer. J Control Release 2016;243:250-68. [PMID: 27746277 DOI: 10.1016/j.jconrel.2016.10.014] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 5.8] [Reference Citation Analysis]
496 Leisy H, Ahmad M, Smith RT. Photopsias during Systemic Bevacizumab Therapy. Case Rep Ophthalmol Med 2016;2016:1926178. [PMID: 27069702 DOI: 10.1155/2016/1926178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
497 Lanza GM, Winter PM, Caruthers SD, Hughes MS, Hu G, Schmieder AH, Wickline SA. Theragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsions. Angiogenesis 2010;13:189-202. [PMID: 20411320 DOI: 10.1007/s10456-010-9166-0] [Cited by in Crossref: 72] [Cited by in F6Publishing: 60] [Article Influence: 6.0] [Reference Citation Analysis]
498 Sleeckx N, de Rooster H, Veldhuis Kroeze EJ, Van Ginneken C, Van Brantegem L. Canine mammary tumours, an overview. Reprod Domest Anim 2011;46:1112-31. [PMID: 21645126 DOI: 10.1111/j.1439-0531.2011.01816.x] [Cited by in Crossref: 95] [Cited by in F6Publishing: 79] [Article Influence: 8.6] [Reference Citation Analysis]
499 Lee SY, Yang CY, Peng CL, Wei MF, Chen KC, Yao CJ, Shieh MJ. A theranostic micelleplex co-delivering SN-38 and VEGF siRNA for colorectal cancer therapy. Biomaterials 2016;86:92-105. [PMID: 26896610 DOI: 10.1016/j.biomaterials.2016.01.068] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 9.5] [Reference Citation Analysis]
500 Ahmed R, Oborski MJ, Hwang M, Lieberman FS, Mountz JM. Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods. Cancer Manag Res 2014;6:149-70. [PMID: 24711712 DOI: 10.2147/CMAR.S54726] [Cited by in Crossref: 30] [Cited by in F6Publishing: 71] [Article Influence: 3.8] [Reference Citation Analysis]
501 Jha SK, Rauniyar K, Chronowska E, Mattonet K, Maina EW, Koistinen H, Stenman UH, Alitalo K, Jeltsch M. KLK3/PSA and cathepsin D activate VEGF-C and VEGF-D. Elife 2019;8:e44478. [PMID: 31099754 DOI: 10.7554/eLife.44478] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
502 Al-Zeheimi N, Naik A, Bakheit CS, Al Riyami M, Al Ajarrah A, Al Badi S, Al Baimani K, Malik K, Al Habsi Z, Al Moundhri MS, Adham SA. Neoadjuvant Chemotherapy Alters Neuropilin-1, PlGF, and SNAI1 Expression Levels and Predicts Breast Cancer Patients Response. Front Oncol 2019;9:323. [PMID: 31106153 DOI: 10.3389/fonc.2019.00323] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
503 Arang N, Gutkind JS. G Protein-Coupled receptors and heterotrimeric G proteins as cancer drivers. FEBS Lett 2020;594:4201-32. [PMID: 33270228 DOI: 10.1002/1873-3468.14017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
504 Masuda Y, Shimizu A, Kataoka M, Arai T, Ishikawa A, Du X, Saito SK, Aki K, Nagasaka S, Mii A, Fujita E, Fukuda Y. Inhibition of capillary repair in proliferative glomerulonephritis results in persistent glomerular inflammation with glomerular sclerosis. Lab Invest 2010;90:1468-81. [PMID: 20644521 DOI: 10.1038/labinvest.2010.130] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
505 Tsukada Y, Nakamura F, Iwamoto M, Terahara A, Higashi T. Patterns of prescribing radiotherapy and bevacizumab in nationwide practice - analysis of 101 designated cancer care hospitals in Japan. J Radiat Res 2016;57:157-63. [PMID: 26661853 DOI: 10.1093/jrr/rrv080] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
506 Shodeinde AB, Murphy AC, Oldenkamp HF, Potdar AS, Ludolph CM, Peppas NA. Recent Advances in Smart Biomaterials for the Detection and Treatment of Autoimmune Diseases. Adv Funct Mater 2020;30:1909556. [PMID: 33071713 DOI: 10.1002/adfm.201909556] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
507 Gururangan S, Fangusaro J, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, Gajjar A, Goldman S, Friedman HS, Packer RJ, Boyett JM, Kun LE, McLendon R. Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study. Neuro Oncol 2012;14:1404-12. [PMID: 23019233 DOI: 10.1093/neuonc/nos213] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
508 Luis de Redín I, Boiero C, Recalde S, Agüeros M, Allemandi D, Llabot JM, García-Layana A, Irache JM. In vivo effect of bevacizumab-loaded albumin nanoparticles in the treatment of corneal neovascularization. Exp Eye Res 2019;185:107697. [PMID: 31228461 DOI: 10.1016/j.exer.2019.107697] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
509 Duong N, Curley K, Brown A, Campanelli A, Do MA, Levy D, Tantry A, Marriott G, Lu B. Decoy exosomes as a novel biologic reagent to antagonize inflammation. Int J Nanomedicine 2019;14:3413-25. [PMID: 31190800 DOI: 10.2147/IJN.S196975] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 6.7] [Reference Citation Analysis]
510 Akturk UD, Tuncer C, Bozkurt H, Sahin OS, Bulut H, Arikok A, Dinc C, Gurer B, Turkoglu E. Blocking VEGF by Bevacizumab Attenuates VEGF-Induced Vasospasm After Experimental Subarachnoid Hemorrhage in Rabbits. World Neurosurg 2020;139:e136-43. [PMID: 32251821 DOI: 10.1016/j.wneu.2020.03.151] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
511 Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal. 2007;19:2003-2012. [PMID: 17658244 DOI: 10.1016/j.cellsig.2007.05.013] [Cited by in Crossref: 614] [Cited by in F6Publishing: 580] [Article Influence: 40.9] [Reference Citation Analysis]
512 Teghom C, Giraud P, Menei P, Medioni J, Elaidi R, Combe P, Oudard S. Carcinome rénal : état des lieux de la prise en charge des métastases cérébrales. Bulletin du Cancer 2012;99:627-34. [DOI: 10.1684/bdc.2012.1596] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
513 Maguire CJ, Chen Z, Mocharla VP, Sriram M, Strecker TE, Hamel E, Zhou H, Lopez R, Wang Y, Mason RP, Chaplin DJ, Trawick ML, Pinney KG. Synthesis of dihydronaphthalene analogues inspired by combretastatin A-4 and their biological evaluation as anticancer agents. Medchemcomm 2018;9:1649-62. [PMID: 30429970 DOI: 10.1039/c8md00322j] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
514 Flaherty KT, Puzanov I. Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma. Biochemical Pharmacology 2010;80:638-46. [DOI: 10.1016/j.bcp.2010.04.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
515 Mamluk R, Carvajal IM, Morse BA, Wong H, Abramowitz J, Aslanian S, Lim AC, Gokemeijer J, Storek MJ, Lee J, Gosselin M, Wright MC, Camphausen RT, Wang J, Chen Y, Miller K, Sanders K, Short S, Sperinde J, Prasad G, Williams S, Kerbel R, Ebos J, Mutsaers A, Mendlein JD, Harris AS, Furfine ES. Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. MAbs 2010;2:199-208. [PMID: 20190562 DOI: 10.4161/mabs.2.2.11304] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 3.8] [Reference Citation Analysis]
516 Nishimura T, Furihata M, Kubo H, Tani M, Agawa S, Setoyama R, Toyoda T. Intracranial hemorrhage in patients treated with bevacizumab: Report of two cases. World J Gastroenterol 2011; 17(39): 4440-4444 [PMID: 22110272 DOI: 10.3748/wjg.v17.i39.4440] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
517 Kim MH, Tsuhako AL, Co EW, Aftab DT, Bentzien F, Chen J, Cheng W, Engst S, Goon L, Klein RR, Le DT, Mac M, Parks JJ, Qian F, Rodriquez M, Stout TJ, Till JH, Won KA, Wu X, Yakes FM, Yu P, Zhang W, Zhao Y, Lamb P, Nuss JM, Xu W. The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett 2012;22:4979-85. [PMID: 22765894 DOI: 10.1016/j.bmcl.2012.06.029] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
518 Kuo H, Shen EP. Long-term topical bevacizumab for prevention of corneal graft rejections. European Journal of Ophthalmology. [DOI: 10.1177/1120672120939504] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
519 Mahfud M, Breitenstein S, El-Badry AM, Puhan M, Rickenbacher A, Samaras P, Pessaux P, Lopez-Ben S, Jaeck D, Figueras J. Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study. World J Surg. 2010;34:92-100. [PMID: 19838754 DOI: 10.1007/s00268-009-0251-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
520 Sorace AG, Saini R, Mahoney M, Hoyt K. Molecular ultrasound imaging using a targeted contrast agent for assessing early tumor response to antiangiogenic therapy. J Ultrasound Med 2012;31:1543-50. [PMID: 23011617 DOI: 10.7863/jum.2012.31.10.1543] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
521 Li D, Xie K, Ding G, Li J, Chen K, Li H, Qian J, Jiang C, Fang J. Tumor resistance to anti-VEGF therapy through up-regulation of VEGF-C expression. Cancer Lett 2014;346:45-52. [PMID: 24333721 DOI: 10.1016/j.canlet.2013.12.004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
522 Simon T, Coquerel B, Petit A, Kassim Y, Demange E, Le Cerf D, Perrot V, Vannier JP. Direct effect of bevacizumab on glioblastoma cell lines in vitro. Neuromolecular Med 2014;16:752-71. [PMID: 25113866 DOI: 10.1007/s12017-014-8324-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
523 Grundy M, Coussios C, Carlisle R. Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer. Expert Opin Drug Deliv 2016;13:999-1013. [PMID: 27080542 DOI: 10.1517/17425247.2016.1167036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
524 Rad FH, Le Buanec H, Paturance S, Larcier P, Genne P, Ryffel B, Bensussan A, Bizzini B, Gallo RC, Zagury D. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci U S A. 2007;104:2837-2842. [PMID: 17301234 DOI: 10.1073/pnas.0611022104] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 3.7] [Reference Citation Analysis]
525 Di Costanzo F, Gasperoni S, Rotella V, Di Costanzo F. Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer. Onco Targets Ther 2009;2:179-88. [PMID: 20616905 DOI: 10.2147/ott.s3863] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
526 Hajirezaei M, Darbouy M, Kazemi B. Cloning and Expression of the Functional Human Anti-vascular Endothelial Growth Factor (VEGF) Using the pcDNA3.1 Vector and the Human Chronic Myelogenous Leukemia Cell Line K562. Protein J 2014;33:100-9. [DOI: 10.1007/s10930-013-9533-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
527 Tarhriz V, Bandehpour M, Dastmalchi S, Ouladsahebmadarek E, Zarredar H, Eyvazi S. Overview of CD24 as a new molecular marker in ovarian cancer. J Cell Physiol 2019;234:2134-42. [PMID: 30317611 DOI: 10.1002/jcp.27581] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 8.5] [Reference Citation Analysis]
528 Yang K, Wu Z, Zhang H, Zhang N, Wu W, Wang Z, Dai Z, Zhang X, Zhang L, Peng Y, Ye W, Zeng W, Liu Z, Cheng Q. Glioma targeted therapy: insight into future of molecular approaches. Mol Cancer 2022;21:39. [PMID: 35135556 DOI: 10.1186/s12943-022-01513-z] [Reference Citation Analysis]
529 Lim JI. MACULAR DEGENERATION: THE LATEST IN CURRENT MEDICAL MANAGEMENT: . Retina 2006;26:S17-20. [DOI: 10.1097/00006982-200607001-00005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
530 Xu H, Tang B, Huang W, Luo S, Zhang T, Yuan J, Zheng Q, Zan X. Deliver protein across bio-barriers via hexa-histidine metal assemblies for therapy: a case in corneal neovascularization model. Mater Today Bio 2021;12:100143. [PMID: 34765961 DOI: 10.1016/j.mtbio.2021.100143] [Reference Citation Analysis]
531 Zhao G, Peery RB, Yingling JM. Characterization and development of a peptide substrate-based phosphate transfer assay for the human vascular endothelial growth factor receptor-2 tyrosine kinase. Anal Biochem 2007;360:196-206. [PMID: 17141171 DOI: 10.1016/j.ab.2006.10.038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
532 Klein D. Vascular Wall-Resident Multipotent Stem Cells of Mesenchymal Nature within the Process of Vascular Remodeling: Cellular Basis, Clinical Relevance, and Implications for Stem Cell Therapy. Stem Cells Int. 2016;2016:1905846. [PMID: 26880936 DOI: 10.1155/2016/1905846] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
533 Grothey A, Allegra C. Antiangiogenesis therapy in the treatment of metastatic colorectal cancer. Ther Adv Med Oncol. 2012;4:301-319. [PMID: 23118806 DOI: 10.1177/1758834012454464] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
534 Kippenberger S, Meissner M, Kaufmann R, Hrgovic I, Zöller N, Kleemann J. Tumor Neoangiogenesis and Flow Congestion: A Parallel to the Braess Paradox? Circ Res 2016;119:711-3. [DOI: 10.1161/circresaha.116.309411] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
535 Lorusso G, Rüegg C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol. 2008;130:1091-1103. [PMID: 18987874 DOI: 10.1007/s00418-008-0530-8] [Cited by in Crossref: 302] [Cited by in F6Publishing: 296] [Article Influence: 21.6] [Reference Citation Analysis]
536 Azimi MS, Myers L, Lacey M, Stewart SA, Shi Q, Katakam PV, Mondal D, Murfee WL. An ex vivo model for anti-angiogenic drug testing on intact microvascular networks. PLoS One 2015;10:e0119227. [PMID: 25742654 DOI: 10.1371/journal.pone.0119227] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
537 Sonaglioni A, Albini A, Fossile E, Pessi MA, Nicolosi GL, Lombardo M, Anzà C, Ambrosio G. Speckle-Tracking Echocardiography for Cardioncological Evaluation in Bevacizumab-Treated Colorectal Cancer Patients. Cardiovasc Toxicol 2020;20:581-92. [PMID: 32519318 DOI: 10.1007/s12012-020-09583-5] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
538 Ando Y, Kawaoka T, Kosaka M, Shirane Y, Johira Y, Miura R, Murakami S, Yano S, Amioka K, Naruto K, Kosaka Y, Uchikawa S, Kodama K, Fujino H, Nakahara T, Ono A, Murakami E, Yamauchi M, Okamoto W, Takahashi S, Imamura M, Chayama K, Aikata H. Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice. Cancers (Basel) 2021;13:3958. [PMID: 34439111 DOI: 10.3390/cancers13163958] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
539 Cheng JS, Tsai WL, Liu PF, Goan YG, Lin CW, Tseng HH, Lee CH, Shu CW. The MAP3K7-mTOR Axis Promotes the Proliferation and Malignancy of Hepatocellular Carcinoma Cells. Front Oncol 2019;9:474. [PMID: 31214512 DOI: 10.3389/fonc.2019.00474] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
540 Hosseini H, Nejabat M, Mehryar M, Yazdchi T, Sedaghat A, Noori F. Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. Clin Exp Ophthalmol 2007;35:745-8. [DOI: 10.1111/j.1442-9071.2007.01572.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 3.3] [Reference Citation Analysis]
541 Anderson AR, Segura T. Injectable biomaterials for treatment of glioblastoma. Adv Mater Interfaces 2020;7:2001055. [PMID: 34660174 DOI: 10.1002/admi.202001055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
542 Levina V, Su Y, Nolen B, Liu X, Gordin Y, Lee M, Lokshin A, Gorelik E. Chemotherapeutic drugs and human tumor cells cytokine network. Int J Cancer 2008;123:2031-40. [PMID: 18697197 DOI: 10.1002/ijc.23732] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 4.4] [Reference Citation Analysis]
543 Weinstein O, Abu Tailakh M, Lifshitz T, Novack V, Levy J. Intravitreal bevacizumab treatment for neovascular age-related macular degeneration and thromboembolic events. Eur J Ophthalmol 2020;30:66-71. [PMID: 30618282 DOI: 10.1177/1120672118823128] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
544 Yamaguchi K, Matsumoto Y, Suzuki R, Nishida H, Omata D, Inaba H, Kukita A, Tanikawa M, Sone K, Oda K, Osuga Y, Maruyama K, Fujii T. Enhanced antitumor activity of combined lipid bubble ultrasound and anticancer drugs in gynecological cervical cancers. Cancer Sci 2021;112:2493-503. [PMID: 33793049 DOI: 10.1111/cas.14907] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
545 Luo F, Li M, Ding J, Zheng S. The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. Front Oncol 2021;11:635731. [PMID: 34631513 DOI: 10.3389/fonc.2021.635731] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
546 Kros JM, Mustafa DM, Dekker LJ, Sillevis Smitt PA, Luider TM, Zheng PP. Circulating glioma biomarkers. Neuro Oncol 2015;17:343-60. [PMID: 25253418 DOI: 10.1093/neuonc/nou207] [Cited by in Crossref: 25] [Cited by in F6Publishing: 46] [Article Influence: 3.1] [Reference Citation Analysis]
547 Liang WC, Dennis MS, Stawicki S, Chanthery Y, Pan Q, Chen Y, Eigenbrot C, Yin J, Koch AW, Wu X, Ferrara N, Bagri A, Tessier-Lavigne M, Watts RJ, Wu Y. Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library. J Mol Biol 2007;366:815-29. [PMID: 17196977 DOI: 10.1016/j.jmb.2006.11.021] [Cited by in Crossref: 98] [Cited by in F6Publishing: 93] [Article Influence: 6.1] [Reference Citation Analysis]
548 Carlsson SK, Brothers SP, Wahlestedt C. Emerging treatment strategies for glioblastoma multiforme. EMBO Mol Med 2014;6:1359-70. [PMID: 25312641 DOI: 10.15252/emmm.201302627] [Cited by in Crossref: 150] [Cited by in F6Publishing: 147] [Article Influence: 21.4] [Reference Citation Analysis]
549 Arizmendez NP, Rudmik L, Poetker DM. Intravenous bevacizumab for complications of hereditary hemorrhagic telangiectasia: a review of the literature. Int Forum Allergy Rhinol. 2015;5:1042-1047. [PMID: 26202958 DOI: 10.1002/alr.21587] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
550 Asai T, Suzuki Y, Matsushita S, Yonezawa S, Yokota J, Katanasaka Y, Ishida T, Dewa T, Kiwada H, Nango M, Oku N. Disappearance of the angiogenic potential of endothelial cells caused by Argonaute2 knockdown. Biochem Biophys Res Commun 2008;368:243-8. [PMID: 18222171 DOI: 10.1016/j.bbrc.2008.01.074] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
551 Lin RC, Rosenfeld PJ. Antiangiogenic therapy in neovascular age-related macular degeneration. Int Ophthalmol Clin 2007;47:117-37. [PMID: 17237677 DOI: 10.1097/IIO.0b013e31802bd873] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]